INDEX

A

Aberdeen Biological Chemical Agent Disposal Facility
  mustard agent container drainage, 597
Abood, Leo
  anticholinergic deliriant research, 424
Abramson, Dr. Harold
  lysergic acid diethylamide research, 413
Acetylcholinesterase
  assays for measuring, 702
  description and mechanism of action, 158, 693
  nerve agent effect on, 158, 244, 316, 693–694
ACGIH. *See* American Conference of Governmental Industrial Hygienists
AChE. *See* Acetylcholinesterase
Acland, K.M.
  uses of lasers in dermatological practice, 284
Acticoat
  mustard agent injury dressing, 280
Activated charcoal
  brevetoxin intoxication treatment, 630
  palytoxin intoxication treatment, 620
  saxitoxin treatment, 627
  tetrodotoxin treatment, 627
Active topical skin protectant
  criteria for, 531–532
  development of, 531
Acute exposure guidance levels
  for chemical agents, 143
Acute respiratory distress syndrome
  sulfur dioxide and, 345
  toxic industrial chemicals and, 354–355
Adams, Maj. Robert
  diphenylaminearsine discovery, 464
AEF. *See* American Expeditionary Forces
AEGLs. *See* Acute exposure guidance levels
Afghanistan
  September 11, 2001, terrorist attacks and, 65, 129
Afghanistan War
  chemical weapons and, 62
AFS. *See* Alternative footwear system
Age factors
  butyrylcholinesterase activity, 164
  erythrocyte cholinesterase, 164
Agency for Toxic Substances and Diseases Registry
  Hazardous Substance Emergency Events Surveillance System, 540
Agent Orange
  estimation of injuries from, 428
  Vietnam War and, 341
Aghajanian, George
  LSD research, 417
Aharoni, A.
  human paraoxonase 1 research, 251
Airplanes
  smoke tanks, 120
  used for chemical attacks, 26, 118–119
Aisne defensive
  chemical attacks, 29
Aisne-Marne offensive
  chemical attacks, 30–31
  division field hospitals, 95
  medical personnel as victims, 102
  US participation (figure), 31
Al Qaeda
  chemical weapons and, 129, 145
  compared with Aum Shinrikyo, 129
  description, 129
Alexander, Lt. Col. Stewart
  Bari disaster and, 105
Alkyl methylphosphonic acids
  nerve agents and, 694, 695, 696, 698
Alkyl MPAs. *See* Alkyl methylphosphonic acids
Alphabet Bomber
  chemical attack description, 127
Alprazolam
  incapacitating effects, 420
Alternative footwear system
  description, 573
Alzheimer's disease
  anticholinesterase drug treatment, 158, 704
  memantine treatment, 228
  physostigmine treatment, 704
  tetrahydroaminacridine treatment, 426
Ambros, Otto
  sarin research, 47, 156
  views on chemical warfare, 49
American Academy of Pediatrics
  forms of terrorism that require immediate attention, 656
  resources, 683–684
American Burn Association
  criteria for chemical burn injuries, 278
American Conference of Governmental Industrial Hygienists
  2-chlorobenzylidene malononitrile exposure guidelines, 447
American Expeditionary Forces. *See also* US Army Medical Department
  Aisne-Marne Offensive and, 30–31
  Battle of Belleau Wood and, 28, 29–30
  Battle of Cambrai and, 24–25
  Battle of Cantigny and, 27, 29
  Battle of Chateau-Thierry and, 28, 29
  Battles of Sommervillier and Ansauville and, 25–26
  Champagne-Marne defensive and, 30
  chemical warfare casualties, 41–42
  earliest reported description involving chemical warfare on (exhibit), 22
  first projector attack on (exhibit), 26
  Headquarters, First Army Corps, memorandum on the evacuation of sick and wounded, 1918 (exhibit), 98
  Lys defensive and, 26–27
  major defensive campaigns, 1918 (table), 89
  major offensive campaigns of the AEF, 1918 (table), 101
  Meuse-Argonne campaign and, 33, 36
  Oise-Aisne offensive and, 32
  1st Gas Regiment, 22, 37
  secret field order no. 41, annex no. 7, issued by the Fifth Division, September 9, 1918 (exhibit), 100
  World War I AEF in offensive and defensive battles involving chemical warfare (table), 23
American Heart Association
  Pediatric Advanced Life Support Course, 682
  recommended values for safe cardiovascular function (table), 542
Aminophylline
  incapacitating agent exposure treatment, 471
  phosgene inhalation treatment, 354
Amitai, Y.
  use of atropine in the pediatric population research, 663–664
AMLs. *See* Area medical laboratories
Ammonia

clinical presentation, 355–356
corticosteroid treatment, 353
gaseous ammonia effects at various concentrations (table), 355
nonmilitary use, 341–342
signs and symptoms of inhalation, 353
AMN. *See* Atropine methylnitrate
Amyl nitrite
cyanide poisoning treatment, 383–384, 394–395, 397, 675–676
Anders, M.W.
phosgene research, 736
Anesthetics. *See also* specific agents
dissociative anesthetics, 419–420
pediatric population and, 665, 667
Angola
use of nerve agents against rebels, 63
Ansauville, Battle of
phosgene and chloropicrin attacks, 25–26
Anthrax
CDC categorization as a category A threat agent, 616
Anthrax attacks
domestic preparedness and, 761
Strategic National Stockpile and, 765
Antibiotics. *See also* Topical antibiotics
chlorine exposure treatment, 673
mustard agent treatment, 672
toxic industrial chemical exposure treatment, 363
Anticholinergic deliriants. *See also* specific agents
ancillary supportive measures for the treatment of delirium (exhibit), 430
compound comparisons, 424–425
diagnosis of syndromes caused by, 428
incapacitating effects, 413, 421, 422–425
mechanism of action, 422, 425
safety of, 427
summary of BZ and fentanyl derivatives (exhibit), 429
testing on volunteers, 424–425
treatment for intoxication, 425–426
Anticonvulsive therapy. *See also specific agents*
nerve agent exposure and, 189–190
Antidote treatment nerve agent autoinjector
nerve agent exposure treatment, 182–186, 192, 193, 194, 518, 520–521, 651, 663
replacement of Mark I kits and, 651, 652
Antioxidants
treatment of mustard agent exposure, 282
Antipsychotic drugs. *See also specific agents*
incapacitating effects, 420
side effects, 420
Anxiety
differential diagnosis of incapacitating agent intoxication, 428
Arab-Israeli Six-Day War
biological warfare and, 58
nerve agent use, 58
Arab-Israeli Yom Kippur War
chemical weapons and, 61
ARDS. *See* Acute respiratory distress syndrome
Area medical laboratories
domestic preparedness role, 763–764
endemic diseases section, 764
nuclear, biological, and chemical section, 764
occupational and environmental health section, 763–764
professional officer filler information system, 764
structure of, 763
Armed Forces Institute of Pathology
1-chloroacetophenone research, 463
Armed Forces Radiobiology Research Institute
CBRNE training program, 768
Arrhythmias
nerve agent exposure and, 179–180
treatment for, 179, 190
ventilatory support, 190
Arsenicals. *See* Lewisite; Phosgene oxime
Arthur, Vice Admiral Stanley
chemical warfare comments, 64
AS. *See* Atropine sulfate
Asahara, Shoko
Aum Shinrikyo and, 127
Ashani, Y.
plasma-derived human butyrylcholinesterase research, 245
Ashton, I.
dibenz*[b,f]*-1,4-oxazepine research, 467
"Assay Techniques for Detection of Exposure to Sulfur Mustard, Cholinesterase Inhibitors, Sarin, Soman, GF, and Cyanide" (Technical Bulletin Medical 296), 693
Assays of adducts to biomolecules
analytical methods, 698–699
analytical methods using adducts to biomolecules (table), 700
application to human exposures, 699–701
methods used to confirm human exposures to nerve agent adducts to biomolecules (table), 701
ATCA. *See* 2-aminothiazoline-4-carboxylic acid
Atkisson, Col. E.J.
AEF 1st Gas Regiment leadership, 22
Atlanta Olympics bomb scare, 754
ATNAA. *See* Antidote treatment nerve agent autoinjector
AtroPen
nerve agent exposure treatment, 182, 663
pediatric population and, 663
Atropine. *See also* Atropine sulfate; Dry powder inhaler atropine
antidote drug card for pediatric dosing of atropine (figure), 683
brevetoxin intoxication treatment, 630
incapacitating effects, 412, 413, 422, 425, 426
pediatric population and, 663–664
saxitoxin treatment, 627
tetrodotoxin treatment, 627
Atropine methylnitrate
soman-induced seizure-related brain damage treatment, 227, 228
Atropine sulfate
adjuncts to, 182
antidote treatment nerve agent autoinjector, 182–186
arrhythmia treatment, 179, 190
asymptomatic persons and, 185
combined with oximes, 183, 188
combined with 2-pyridine aldoxime methyl chloride, 183
cyclosarin exposure and, 202
dosage considerations, 182–186
eye pain and, 192
goal of therapy, 184–185
inhalational exposure to vapor treatment, 185
IV delivery of, 180
Mark I kits, 182–186, 188, 190, 192, 194, 663
mechanism of action, 182, 316
medical aerosolized nerve agent antidote, 186, 192
nerve agent exposure treatment, 175, 182–186, 244, 316
organophosphorus compound exposure treatment, 184
pediatric population and, 195
routes of administration, 193–194
side effects, 182–183
topical application of, 190
ventilatory support and, 181, 186, 193
aTSP. *See* Active topical skin protectant
Atta, Gen. Qassim

chlorine gas attack and, 66
Aum Shinrikyo
chemical attacks against judges, 127–128, 695
compared with Al Qaeda, 129
sarin attack in the Tokyo subway, 4, 125, 128, 158, 178, 181–182, 193, 196–197, 223, 244, 316, 317, 321, 492, 518, 540, 657, 695–696, 699, 754
Austria
cyanogen bromide introduction, 373
Aviado, D.
incapacitating agent research, 442
Aviado, D.M.
incapacitating agent research, 442

B

Babad, H.
phosgene research, 345
Baille, V.
soman-induced brain injury, 224–225
Baker, Secretary of War Newton D.
Chemical Warfare Service and, 43
BAL. *See* British antilewisite
Balali-Mood, M.
mustard exposure research, 313, 315
BALF. *See* Bronchoalveolar lavage fluid
Ballantyne, B.
dibenz*[b,f]*-1,4-oxazepine research, 467, 468
hydrogen cyanide research, 354
1-chloroacetophenone research, 460, 461
2-chlorobenzylidene malononitrile research, 451
Ballough, G.P.
soman-induced brain injury, 225
Barbiturates. *See also specific agents*
description and incapacitating effects of, 418
LSD intoxication treatment, 417
safety margin, 418
Barlow, R.J.
uses of lasers in dermatological practice, 284
Basic Personal Equipment, 561
Baskin, S.I.
cyanide poisoning treatment, 396
Bass, Col. Sampson
Program Manager for Demilitarization of Chemical Materiel and, 141
Basson, Dr. Wouter
use of 3-quinuclidinyl benzilate by Iraq, 413
Batrachotoxin
chemical structure (figure), 632
laboratory findings, 633
lethality of, 633
mechanism of action, 632
monitoring, 633
physical examination and, 632–633
poison blow gun dart use, 632
protection, 633
sodium channel effects, 617
sources, 632
stability, 633
surveillance, 633
synthesis, 632
toxicity, 632
treatment, 633
Baud, F.J.
cyanide poisoning research, 396
Baxter Healthcare Corporation
plasma-derived human butyrylcholinesterase production, 653
BChE. *See* Butyrylcholinesterase
Behavioral and psychological changes
categorization of, 176
cyanide poisoning and, 393–394
effects of nerve agent exposure, 175–176
plasma-derived human butyrylcholinesterase and, 248–249
Belgian Consensus on SE
status epilepticus treatment recommendations, 231
Belladonna alkaloids. *See* Anticholinergic deliriants
Belleau Wood, Battle of
chemical attacks, 29–30
overview and detailed maps (exhibit), 28
Bellevue Hospital Center
pediatric nerve agent antidote dosing schedule, 684
Benzodiazepines. *See also specific agents*
hypothermia and, 548–549
incapacitating effects, 420
LSD intoxication treatment, 417
Berber war
description, 42–43
Berthollet, Comte Claude-Louis
synthesis of cyanogen chloride, 116
Beswick, F.W.
2-chlorobenzylidene malononitrile research, 450
Bhopal, India
accidental release of methyl isocyanate, 131, 134, 326, 347
Biel, John
anticholinergic deliriant research, 424
Bigeye bombs
research on, 123, 125
bin Laden, Osama
formation of Al Qaeda and, 129
September 11, 2001, terrorist attacks and, 65
Binary chemical weapons
"Bigeye" bomb, 123, 125
description, 3, 123
development of, 122–124
US Congress restrictions on, 124
US Congress review of, 124
Bing, Oscar
LSD research, 417
Bio Shield towelettes
incapacitating agents and, 470–471
Biobrane
mustard agent injury dressing, 280
Biological warfare
Arab-Israeli Six-Day War and, 58
"Biotechnology: Impact on Biological Warfare and Biodefense," 420–421
chemical weapons comparison, 126
Nixon's ban on biological warfare agents, 138
World War I and, 37
Biological Weapons Convention
description, 137–138
Soviet Union and, 61–62
Bioregulators
incapacitating effects, 420–422
Bioscavengers
advantages of enzymes, 245
catalytic type, 250–251
categories of, 245
free radical scavengers, 232
plasma-derived stoichiometric type, 245–249
Project BioShield, 251
recombinant stoichiometric type, 249–250
"Biotechnology: Impact on Biological Warfare and Biodefense," 420–421
Bis-(2-chloroethyl)sulfide. *See* Mustard agent

Biskup, R.C.
dibenz*[b,f]*-1,4-oxazepine research, 468
Black, R.M.
blood sample analysis for mustard agent, 723
urine sample analysis for mustard agent, 711, 712, 716, 717
Black vinyl overboots
description and uses, 573
Blackford, Lt. Col. William W.
chemical weapon use and, 12
Blair, Prime Minister Tony (Great Britain)
warning to the UN on Iraq's weapons of mass destruction program, 66
Blister agents. *See* Vesicants
Blood cholinesterases
butyrylcholinesterase, 163–164
erythrocyte cholinesterase, 164
inhibition in, 164–166
nerve agent scavenger activity, 164
RBC-ChE monitoring, 161, 163
relation of cholinesterase activity to vomiting after exposure to VX (table), 166
relation of effects of nerve agent exposure to erythrocyte cholinesterase activity (table), 166
relation to signs and symptoms of nerve agent exposure, 165–166
time course of inhibition, 165
vomiting and, 165–166
Blood sample analysis
analytical methods, 718–721
application to human exposure, 721–726
benefits of, 692
collection issues, 692
cyanide poisoning, 731, 733–734
guidelines for collection, 739
lewisite exposure, 728, 731
mustard agent exposure and, 718–726
published reports (1997-2006) of laboratory analysis of human blood samples following suspected exposure to sulfur mustard (table), 727
sample considerations, 739
sample preparation methods for the gas chromatographic-mass spectrometric analysis of sulfur mustard adducts to blood biomolecules (exhibit), 724–725
sample preparation procedure for sulfur mustard adducts to deoxyribonucleic acid in blood (exhibit), 722
Bolimov, Battle of
chlorine gas attacks, 17
T-shells used at, 14
Bone marrow
mustard agent exposure effects, 288–290, 669, 672
Boomfield, C.A.
butyrylcholinesterase research, 245
Boots
alternative footwear system, 573
black vinyl overboots, 573
medical problems and, 573
risk of falls and, 573
Borris, D.J.
ketamine research, 230
Botulinum neurotoxin
CDC categorization as a category A threat agent, 616
Bowers, M.B.
nerve agent exposure research, 320
2-chlorobenzylidene malononitrile research, 452
Boyer, A.E.
urine sample analysis for mustard agent, 711
Boyton, Capt. E.C.
chemical weapon use and, 12
Branch Davidian compound, Waco, TX
FBI attack on, 125
Brandeis, R.
plasma-derived human butyrylcholinesterase research, 249
Brevetoxin
chemical structure (figure), 629
laboratory findings, 630
mechanism of action, 629
monitoring, 630
physical examination and, 629–630
protection, 631
red tide blooms and, 628, 629–630, 631
routes of exposure, 629–630
signs and symptoms of intoxication, 630
sodium channel effects, 617
stability, 631
surveillance, 631
synthesis, 628–629
toxicity, 629
treatment, 630–631
Brisebois, R.J.
mustard agent exposure treatment, 279
British antilewisite
lewisite exposure treatment, 291, 293, 523, 667
Bronchoalveolar lavage fluid
inhalational injury from toxic industrial chemicals and, 348
Broselow, Dr. James
Chemical Warfare Involving Kids Response Project and, 681
Broselow-Luten system
antidote drug card for pediatric dosing of atropine (figure), 683
availability of, 681–682
description, 681
generic needs of children in a disaster situation and, 681–682
logistical difficulties and, 681–683
specific needs of children in a chemical disaster and, 682–683
steps involved in administering a dose of medication (figure), 682
Browder burn severity assessment, 282
Brussels Convention
description, 136
BTX. *See* Batrachotoxin
BuChE. *See* Butyrylcholinesterase
Budesonide
chlorine inhalation treatment, 353
Bulgaria
accidental release of chloropicrin in Sofia, 443, 455
Bullard, Maj. Gen. Robert
comments on gas attacks, 26
gas attack order, 22
gas training for troops and, 22
Bullene, Maj. Gen. Egbert
Korean War comments, 54
Buscher, H.
long-term health effects of mustard, 312, 314
Bush, Pres. George H.W.
chemical weapons destruction plan, 138
Bush, Pres. George W.
National Incident Management System and, 492
Project BioShield and, 251
US Department of Homeland Security creation and, 755
warning to the UN on Iraq's weapons of mass destruction program, 66
Butyrylcholinesterase. *See also* Plasma-derived human butyrylcholinesterase
biomolecule assays and, 700–701

bioscavenger use, 245, 706
description, 158
gender differences in activity of, 164
physiological role, 163
succinylcholine and, 164
synthesis of, 163–164
BZ. *See* 3-quinuclidinyl benzilate

C

CaE. *See* Carboxylesterase
CAIs. *See* Chemical accidents or incidents
Calabar bean
use as a nerve agent, 156
Calamine lotion
mustard agent exposure treatment, 670
California
accidental chloropicrin exposure in Kern, CA, 456, 457
Calmatives. *See* Bioregulators
Cambrai, Battle of
chemical warfare, 24–25
trench conditions, 24
CANA. *See* Convulsive Antidote, Nerve Agent injector
Canada
Russia's elimination of chemical weapons and, 145
Canadian Department of National Defence
Reactive Skin Decontamination Lotion and, 652–653
Cannabinoids
description and effects of, 418
Cantigny, Battle of
chemical attacks, 27, 29
Capacio, B.R.
blood sample analysis of mustard agent exposure (figure), 725
Caplin ammonia inhalation classification, 355
Capsaicin. *See* Oleoresin capsicum
Carbamates
characteristics of, 198–199
chemical structure (figure), 198
compounds included, 158
mechanism of action, 161, 198
uses of, 158
Carbon monoxide gas
Germany's experimental testing on human subjects in concentration camps, 105
Carboxylesterase
bioscavenging use, 246
Carcinoma
dibenz*[b,f]*-1,4-oxazepine exposure and, 468–469
mustard agent exposure and, 312–314, 313–314, 315–316
1-chloroacetophenone and, 461
palytoxin and, 619
2-chlorobenzylidene malononitrile and, 449
Cardiovascular system
American Heart Association recommended values for safe cardiovascular function (table), 542
arrhythmias, 179–180
batrachotoxin effects, 633
brevetoxin effects, 630
change in the electrocardiogram caused by the presence of cyanide in the tissue (figure), 392
cyanide poisoning effects, 391–393
effects of nerve agent exposure, 179–180
electrocardiogram from a cyanide-intoxicated individual (figure), 392
heart rate, 180
incapacitating agent exposure effects, 472
palytoxin effects, 619, 620
paralytic shellfish poisoning effects, 626
saxitoxin effects, 623, 627
tetrodotoxin effects, 623, 627
Carfentanil
description and incapacitating effects, 419
Cassava root
cyanide exposure and, 323, 374, 390, 731
Castro, J.A.
1-chloroacetophenone research, 460
Catalytic bioscavengers
chloroperoxidase, 250
compared with stoichiometric scavengers, 250
human paraoxonase 1, 250–251
sources of, 250
CBRNE incidents. *See* Chemical, biological, radiological, nuclear or explosive incidents
CDC. *See* Center for Disease Control and Prevention
Center for Disease Control and Prevention. *See also* National Institute for Occupational Safety and Health
classification of bioterrorism agents/diseases (table), 617
demilitarization of chemical agents and, 142, 143
Enhanced Surveillance Program, 622
Laboratory Response Network and, 765–766
list of toxic chemicals and chemical agents, chemical characteristics, and medical first aid and antidote treatment, 761
phosgene inhalation treatment guidelines, 354
sample collection, shipping, and storage guidelines, 739–741
Strategic National Stockpile and, 765
threat agent categorization, 616–617
Center for Pediatric Emergency Medicine
pediatric nerve agent antidote dosing schedule, 684
Central Intelligence Agency
lysergic acid diethylamide and, 414
saxitoxin capsules and, 628
terrorist interest in food and water contamination, 672
Central nervous system
batrachotoxin effects, 633
brain lesions, 178
cyanide poisoning effects, 393–394
electroencephalographic effects of nerve agent exposure, 176–177, 321–322
hypoxia, 178–179, 180, 287
long-term effects of nerve agent exposure, 177–179
mustard agent effects, 276, 290, 315, 669
nerve agent effects, 175–179, 317
neuropsychiatric symptoms, 315
organophosphate insecticide effects, 317
palytoxin effects, 621
pediatric exposure to toxic agents and, 659
polyneuropathy, 317
saxitoxin effects, 623, 625–626
seizures, 178–179
soman effects, 416
tetrodotoxin effects, 623, 625–626
CG. *See* Phosgene
Chad
Libya's use of chemical weapons against, 63
Champagne-Marne defensive
chemical attacks, 30
US participation (figure), 31
Chapman, A.J.
1-chloroacetophenone research, 462
Charles XII, King (Sweden)
use of toxic smoke projectiles, 11
Chateau-Thierry, Battle of
chemical attacks, 29
overview and detailed maps (exhibit), 28
ChE inhibitors. *See* Cholinesterase inhibitors

Chemical, biological, radiological, nuclear or explosive incidents
detection and response capabilities of DoD, 761–762
effective information flow and, 754
reach back capabilities of DoD, 763
training and education issues, 767–770
Chemical Accident or Incident Response and Assistance Operations
chemical surety resource, 594
level 1 medical care, 609
Medical Management of Chemical and Biological Casualties Course, 594–595
Toxic Chemical Training Course for Medical Personnel, 594–595
Chemical accidents or incidents
Chemical Stockpile Emergency Preparedness Program, 609
coordination required, 607–608
decontamination procedure, 609
emergency medical care, 608
information needed, 608–609
levels of medical care, 609
medical aspects of response to, 607–609
medical response teams and, 607
planning phase, 607
Chemical agent detector kits
description and uses, 576–577
Chemical and biological protected shelters
composition of, 585–586
description, 585
Chemical Biological Medical Systems Joint Project Management Office
responsibilities, 4
Chemical Corps
air and ground delivery systems for chemical weapons, 120
cannabinoid research, 418
changes of the 1970s, 60–61
Chemical Warfare Service name changed to, 53
incapacitant program, 55–56
Korean War and, 54
lysergic acid diethylamide testing, 416–417
medical research on human volunteers during the 1950s, 55
mission, 53–54
1950s changes in, 54–55
planned changes of the 1970s, 60–61
sarin production, 55
3-quinuclidinyl benzilate testing, 414
training and education in CBRNE and, 767
US Army reorganization and, 56–57
Vietnam War and, 57
Chemical defense equipment
collective protection, 584–587
criteria for selection of, 560
decontaminable litters, 588–589
decontamination equipment, 581–584
detection and warning systems, 575–579
individual chemical patient resuscitation devices, 587–588
individual protective equipment, 561–575
integrated approach to protection, 560
patient protective wraps, 587
principles for optimal outcome, 560
respirators, 560
timely detection need, 560
toxic industrial material protection, 580–581
Chemical personnel reliability program
description, 605
medical authority recommendations, 605
medical support of, 605, 607
potentially disqualifying factors, 605
Chemical protective glove set
decontamination of, 574
description and composition of, 573
Chemical Security Analysis Center
description and role, 767
Chemical Stockpile Emergency Preparedness Program
alternative year exercises, 766–767
chemical accidents or incidents and, 609
chemical depots, 766–767
DoD role, 766
federally managed exercises, 766
FEMA role, 766
Chemical Surety (AR 50-6), 594
Chemical terrorism. *See* Terrorist attacks
"Chemical Warfare in Southeast Asia and Afghanistan" (Haig), 62
Chemical Warfare Involving Kids Response Project
description, 681
"Chemical Warfare Respiratory Protection: Where We Were and Where We Are Going," 561
Chemical Warfare Service
airplane attack testing, 119
chemical agent and weapon stockpiling, 119
chemical weapon delivery system improvement, 118
complaints about gas mask effectiveness, 83
creation of, 22, 90, 117, 761
divisions, 22
Gas Service, 22, 89–90
Italian-Ethiopian War and, 46
low point in funding for, 44
monitoring of Japan's use of chemical weapons in China, 52
name change to Chemical Corps, 53
need for permanent status of, 43–44, 53
1920s and, 43–44
organophosphorus compound designations, 47
plans to use poison gas on Japan, 52–53
staff statistics, 37
standardization of chemical agents, 44
training of troops during World War II, 53
Chemical weapons. *See also* Development of chemical weaponry; *specific chemicals; specific conflicts*
agent toxicity determination, 657
capabilities of nations, 131–132
categories of, 10
"chemical threat" definition, 130
comparative volatility of chemical warfare agents (table), 135
compared with biological weapons, 126
delivery systems, 80, 117–118, 119, 120–122, 123, 130, 132–133, 157
demilitarization of, 609–611
description, 2, 10
desirable outcomes of the use of, 2
direct injuries from, 10
effectiveness as weapons, 79
features of, 133
future threats, 4
general principles of chemical exposure, 657
How to Tell the Gases poem by Maj. Fairfax Downey (exhibit), 41
indirect injuries from, 10
Joint Program Executive Office role, 4
military advantages of, 2
military chemical agents, 133–134
modern chemical warfare agents (table), 134
nonpersistent agents, 135
persistent agents, 135–136, 244
physical properties of chemical agents, 134–136
political and legal ramifications of an attack, 692
potential for use in the civilian sector, 692

psychological effect of, 2, 19–20
stockpile management, 3–4
tactical and strategic use of, 132
terrorist threat, 4
timeline of agents, 2–3
toxin comparison, 616–617
US stockpile agent destruction (table), 143
volatility of, 134–135, 168
wind and weather considerations, 80, 117, 131, 135–136
Chemical weapons agreements
Biological Weapons Convention, 137–138
Chemical Weapons Convention, 138–145
Geneva Protocol, 136–137
UN Disarmament Committee, 137
US-Soviet weapons destruction agreement, 138
Chemical Weapons Convention
basic tenets, 139
chemical demilitarization, 141–145, 766
development of, 138
disarmament provisions, 3
fentanyl and, 419
governmental proliferation threat, 145
implementation issues, 140–141
inspection and verification, 140
noncompliance issues, 140, 141
nongovernmental proliferation, 145
prohibition on the use of tear gas in combat, 66, 431, 442
ratification of, 138–139, 157
schedule and category of chemicals and chemical weapons (table), 139
schedule of implementation plan (table), 140
scheduling issues, 139–140, 157
signing of, 65, 157
"toxin" definition, 614
Chemically protected deployable medical system
composition of, 584–585
description, 584
M28 collective protection equipment, 585
Chen, K.K.
cyanide poisoning research, 383, 384–385
Children. *See* Infants and children
China
ancient use of toxic smoke, 10, 12, 78
chemical weapon production, 48
incapacitating agent use, 443
invasion by Japan in 1937, 46
Chlorine
accidental release of, 131, 134
advantages of as a weapon, 126, 342
Battle of Loos and, 18–19
clinical presentation of exposure to, 672–673
combined with phosgene, 341
development of, 14
discovery of, 116
general mechanisms of toxic gas exposure (figure), 347
nerve agents compared with, 181
nonmilitary uses, 342
pediatric population and, 673
Second Battle of Ypres and, 14–18, 21, 80–82
signs and symptoms of exposure, 359
treatment for inhalation of, 353, 673
US production of, 117
"white star" mixture with phosgene, 19–20
World War I use, 2, 14–19, 21, 80–82, 83
Chloroacetophenone
nonmilitary uses, 342
overall effects of, 342
Yemen Civil War and, 57, 58
Chloroperoxidase
VX nerve agent and, 250
Chloropicrin
accidental release of, 443, 455
agricultural uses, 443, 455
characteristics of PS, CN, DM, and CR (table), 458–459
chemical structure (figure), 456
chloropicrin syndrome, 456
clinical effects, 456–457
deployment methods, 456
development and properties of (exhibit), 20
earliest reported description involving chemical warfare on the AEF (exhibit), 22
introduction of, 20
long-term effects, 457
mechanism of action, 455
physical characteristics, 456
physiological effects, 456
safes and vaults and, 455
severe medical complications, 457
synthesis of, 117, 443
toxicity of, 443
US production of, 117
World War I use, 25–26, 455
Chlorovinylarsonous acid
lewisite exposure and, 728
published analytical approaches for the analysis of CVAA in urine (figure), 729
sample preparation methods for gas chromatographic/mass spectrometric analysis of CVAA (exhibit), 730
Chlorpromazine
LSD intoxication treatment, 417
Cholinesterase analysis
colorimetric assays in the clinical laboratory, 702, 704
electrometric ChE assay, 704
Ellman assay, 702
huperzine A, 704–706
laboratory and field assays routinely used by the US Army and their required processing (figure), 703
mass spectrometry, 701–702
organophosphorus compounds, 701–706
pretreatment therapy for nerve agent poisoning, 704–706
Test-Mate kit, 702, 704
Walter Reed Institute of Research Whole Blood Assay, 702, 705
Cholinesterase inhibitors. *See also* Nerve agents; *specific agents*
blood cholinesterases, 161–166
case report: accidental exposure of a man to liquid soman (exhibit), 162–163, 312
cholinesterase in tissue, 158
compounds, 158–159
development of, 46–47
diagram of neuromuscular conduction (figure), 160
mechanism of action, 159–161
pharmacology of, 158–168
reversible and irreversible types, 156
Cholinesterases
equine serum butyrylcholinesterase, 245
fetal bovine serum AChE, 245
plasma-derived human butyrylcholinesterase, 245–249
Cholinolytic 3-quinuclidinyl benzilate
perfluoroisobutylene inhalation treatment, 354
Church, Maj. J.R.
Chemical Warfare Service leadership, 90
Churchill, Sir Winston
plans for gas warfare during World War II, 52
City of New York Bureau of Emergency Medical Services

pediatric nerve agent antidote dosing schedule, 684
City of New York Fire Department
pediatric nerve agent antidote dosing schedule, 684
Civil War. *See* US Civil War
CK. *See* Cyanogen chloride
Clark, M.G.
plasma-derived human butyrylcholinesterase research, 249
Clean Air Act
destruction of chemical weapons stockpile and, 610
Clermont
tetraethyl pyrophosphate testing, 46, 156
Clinton, Pres. Bill
presidential decision directives outlining policy for deterring and responding to terrorism, 754
Clonidine
incapacitating effects, 421
Cluster bombs
chemical weapon delivery, 120, 122
CN. *See* chloroacetophenone; 1-chloroacetophenone
Cobalt EDTA
cyanide poisoning treatment, 385, 397
Cobalt salts
cyanide poisoning treatment, 397
Cochrane, Capt. Charles
batrachotoxin description, 632–633
Cochrane, Rexmond
Battle of Cantigny and, 27
Cohn Fraction IV-4 paste
plasma-derived human butyrylcholinesterase source, 247, 249, 251
Cole, T.J.
2-chlorobenzylidene malononitrile research, 450
Colgrave, H.F.
dibenz*[b,f]*-1,4-oxazepine research, 467, 469
Collective protection
categories of, 584
chemical and biological protected shelters, 585–586
chemically protected deployable medical system, 584–585
collectively protected expeditionary medical support, 585
M20 simplified collective protection equipment, 586–587
modular general purpose tent system chemical-biological protective liner system, 587
tactical application, 584
Collectively protected expeditionary medical support
description, 585
Colombian poison dart frogs
batrachotoxin source, 632
COLPRO. *See* Collective protection
ComboPen
2-pyridine aldoxime methyl chloride administration, 187
Cone, D.C.
summary of triage systems, 517
Conner, M.W.
hexachloroethane smoke research, 327
Convulsive Antidote, Nerve Agent injector
diazepam administration, 189–190
nerve agent exposure treatment, 651
Cooper, G.J.
wound decontamination research, 538–539
Cooper, W.C.
organophosphate insecticide exposure research, 320
Corson, B.B.
2-chlorobenzylidene malononitrile research, 444
Corticosteroids. *See also specific agents*
ammonia inhalation treatment, 353
brevetoxin intoxication treatment, 631
chlorine exposure treatment, 673
incapacitating agent exposure treatment, 471
mustard agent exposure treatment, 282
phosgene inhalation treatment, 354, 363
toxic industrial chemical exposure treatment, 363
The Covenant, the Sword, and the Arm of the Lord
chemical attack plan, 127
CP EMEDS. *See* Collectively protected expeditionary medical support
CR. *See* Dibenz*[b,f]*-1,4-oxazepine
Creasy, Maj. Gen. William
lysergic acid diethylamide research, 414
Crone, H.D.
decontamination research, 529
CS. *See O*-chlorobenzylidene malononitrile; 2-chlorobenzylidene malonitrile
CSA. *See* The Covenant, the Sword, and the Arm of the Lord
CSEPP. *See* Chemical Stockpile Emergency Preparedness Program
Curran, D.
anticholinergic deliriant research, 422
Currie, W.D.
phosgene research, 738
Cushing, Dr. Harvey
account of Royal Army Medical Corps capabilities, Flanders, Belgium, May 5, 1917 (exhibit), 88
chemical attack observations, 101
initial impressions of mustard agent, 88–89
observations of the Second Battle of Ypres, 82
CVAA. *See* Chlorovinylarsonous acid
CWC. *See* Chemical Weapons Convention
CWS. *See* Chemical Warfare Service
Cyanide. *See also* Cyanogen chloride; Hydrogen cyanide
accidental exposures, 374
advantages and disadvantages of, 3, 126
analytical methods for determining cyanide in biological samples (table), 732–733
chemical, physical, environmental, and biological properties (table), 372
conventional wounds contaminated with, 523
description, 322, 731
dietary issues, 323, 372–373, 374, 389
endogenous cyanide concentrations for smokers and non-smokers (table), 381
executions and suicides and, 373–374
"gas chambers" and, 373–374
Germany's experimental testing on human subjects in concentration camps, 105
goiter and, 324
historical use, 372–373
long-term exposure to, 323–324
long-term health effects, 322–324
mechanism of action, 343, 397, 731
mechanism of toxicity, 673–674, 731
military use, 372, 373
pharmacokinetics and pharmacodynamics, 376
physiology, 322
quick-kill properties, 373
reference range values, 734
routes of exposure, 322
sources, 372, 374, 731
terrorist plots using, 4
tobacco smoke and, 323, 324, 374
toxicity, 377
toxicodynamic effects (figure), 384
Tylenol poisoned with, 373
uses for, 673
volatility of, 373
World War I use, 372, 373

Zyklon B development, 15
Cyanide poisoning
analytical methods, 377, 731–734
analytical methods to identify cyanide and its metabolites in biological fluids (table), 378–379
antidotal treatment, 383, 518–519, 675–676
antidotes useful in acute cyanide poisoning (table), 395
biochemical basis, 374–377
blood sampling issues, 377, 379–381, 382, 387
cardiac toxicity, 391–393
case synopses, 388–389
change in the electrocardiogram caused by the presence of cyanide in the tissue (figure), 392
clinical presentation and management of casualties, 381–386, 518–519, 674, 731
computational models of cardiac tissue, 392–393
Cyanokit treatment, 676
decontamination, 386–387
detection of cyanide and cyanide metabolites, 377–381
effect of cyanide on a ventricular cell (figure), 392
electrocardiogram from a cyanide-intoxicated individual (figure), 392
enzyme inhibition, 382–383
fire victims and, 390–391, 731
fundamentals of cyanide antidote therapy (figure), 385
hemodialysis treatment, 383
histopathologic changes in cardiac tissue, 391–392
laboratory findings, 387, 674
lethal dose, 383
long-term effects, 387–389
metabolic routes, 376, 731
methemoglobin former treatment, 394–396
mnemonic for recognition of cyanide toxicity (exhibit), 675
mortality from, 322, 376, 381, 731
mouth-to-mouth resuscitation and, 675
multistage antidote kit treatment for managing unconscious, cyanide-exposed patients (table), 675
neurological/psychological responses to cyanide and its countermeasures, 393–394
oxygen therapy, 385
patient transport/evacuation, 387
pediatric considerations, 389–390, 674–676
plot against the US Embassy in Italy, 128
polyintoxications, 390–391
procedures for collecting and storing blood samples for delayed cyanide analysis (exhibit), 382
protection of rescuers, 382
schematic diagram of possible detoxification reaction for cyanide in a theoretical cell (figure), 375
specific antidotes, 394–397
supportive treatment, 323, 383, 674, 675
survivability of, 381–382, 388–389
symptoms of severe ingestions, 323
therapy principles, 381–386
thiocyanate and, 380
treatment, 674–676
triage considerations, 386, 518–519, 521, 522, 523
2-aminothiazoline-4-carboxylic acid and, 376
US approach to cyanide antidotes (table), 386
variation of sodium nitrite and sodium thiosulfate dose with hemoglobin concentration (table), 676
wound decontamination and, 538
Cyanogen bromide
introduction of, 373
Cyanogen chloride
delayed toxic effect, 373
discovery of, 116
introduction of, 18
synthesis of, 116
US troop training and, 53
World War I use, 373
Cyclohexylmethyl phosphonofluoridate. *See* Cyclosarin
Cyclosarin
aging time, 202
chemical structure (figure), 694
hydrolysis pathway of sarin, soman, and cyclosarin (figure), 696
Iraq's production of, 202
polyneuropathy and, 317
synthesis of, 157
toxicity and speed of action, 156, 168, 693
treatment of exposure to, 202
volatility of, 168
Cysteine
phosgene exposure and, 736
Cytoxan
similarity of mustard agent to, 313

D

DA PAM 40-8. *See Occupational Health Guidelines for the Evaluation and Control of Occupational Exposure to Nerve Agents GA, GB, GD, and VX*
DA PAM 40-173. *See Occupational Health Guidelines for the Evaluation and Control of Occupational Exposure to Mustard Agents H, HD, and HT*
DA PAM 50-6. *See Chemical Accident or Incident Response and Assistance Operations*
DA PAM 385-61. *See Toxic Chemical Agent Safety Standards*
DAET. *See* Diisopropyl aminoethanethiol
Dakin solution
treatment of mustard agent injuries, 280–281, 671
Dantrolene
combined with diazepam, 228
dosage considerations, 227
soman-induced seizure-related brain damage treatment, 227–228
Dark, Dr. Eric P.
personal account of a chemical attack (exhibit), 102
Datura
use as an incapacitating agent, 413
Davies, D.R.
nerve agent research, 317
Davy, Sir Humphry
synthesis of phosgene, 116
Debridement
enzymes and, 284–285
lasers and, 284
powered dermabrasion, 284
treatment of mustard agent injuries, 280, 282, 283–285, 290, 670–671
wound decontamination and, 539
Decontaminable litters
description and uses, 588–589
Decontamination equipment
equipment decontamination, 582–583
joint service personnel skin decontamination system, 582
M291 skin decontamination kits, 533, 536, 581
methods in development, 583–584
patient thorough decontamination, 543–546
pediatric population and, 661, 678
personnel decontamination, 581–582
Decontamination of chemical casualties
action of chemical agents on the skin, 529–530
air heaters and, 550

ambient temperature issues, 548–550
appropriate uses for military decontaminants (table), 535
barrier skin creams, 530–532
casualty decontamination (figure), 502
chlorine exposure and, 673
civilian workers and, 528–529
cold shock and, 548–549
cold weather and, 548–550
common problems with potential decontaminants, 533
Contaminated Casualty Decontamination Course, 763
cyanide poisoning and, 386–387, 675
decontamination methods based on ambient temperature (table), 550
decontamination shelters, 544–546, 552
description, 528, 551
desirable traits of a skin decontaminant (exhibit), 534
detection devices, 544
dry decontaminants, 534, 536
equipment for, 543–546, 581–584
establishing a patient thorough decontamination area, 546–548
field management of chemical casualties and, 497, 498–500, 501–504, 505, 506
glove issues, 539
hypothermia and, 548–549, 677
immediate level, 500, 528
incapacitating agents and, 469–471, 520
individual protective ensemble and, 528
methods of decontamination, 532–537
military and civilian decontamination procedures, 528–529
minimal decontamination procedures based on agent characteristics (table), 498
mustard agent and, 277, 312, 670
nerve agent exposure and, 180–181
objectives of, 532
oxidation, 537
packaged wet decontaminants, 536–537
palytoxin and, 620, 621
patents covering work on active topical skin protectant at the US Army Medical Research Institute of Chemical Defense (table), 532
patient operational decontamination level, 500, 528, 529
patient thorough decontamination level, 500, 539–548
pediatric population, 670, 676–678
placement of teams and areas, 514–516, 547
purposes of, 528
soap and water (hydrolysis), 533–534, 544, 551
special populations and, 550–551
time after exposure and, 528
triage issues, 513–516, 677
warming tents, 549
waste water disposal, 546–547
water concerns, 546–547
wound decontamination, 538–539
zones for, 677
Decontamination shelters
fixed facilities and, 545–546
uses of, 544–545
Defense Medical Readiness Training Institute
CBRNE training program, 768
Defense Threat Reduction Agency
Defense Nuclear Weapons School, 769
medical mission, 4
responsibilities, 646
Deliriants. *See* Anticholinergic deliriants
Delivery systems
agent vaporization (figure), 134
airplane smoke tanks, 120
base ejection, 132
bulk release, 132
chemical rockets, 120, 157
cluster bombs, 120, 122, 157
drones, 122
explosive release, 132
four modes of chemical agent release (figure), 133
generator clusters, 122
improvised explosive devices, 130, 145, 580
land mines, 120–121, 157
projectors, 26, 118, 119, 123, 157
rocket program, 121–122, 157
spray delivery, 132, 157
spray tanks, 120
toxic smokes, 10–11, 134
trench mortars, 26, 118, 119
typical German chemical cylinder set up and ready for discharge (figure), 80
vulnerability of battlefield areas, 132
Demilitarization of chemical agents
occupational safety issues, 142
Russian program, 144–145
US program, 141–143, 766
Democratic National Convention of 2004
CDC Enhanced Surveillance Program data, 622
Deoxyribonucleic acid
mustard agent injury and, 264–265, 312, 315–316, 718–721
sample preparation procedure for sulfur mustard adducts to deoxyribonucleic acid in blood (exhibit), 722
DEPMEDS. *See* Chemically protected deployable medical system
Dermatological effects. *See* Skin effects
Despretz, Cesar-Mansuete
synthesis of mustard agent, 116–117, 260
Detection and warning systems
point detectors, 575–577
standoff detectors, 577–579
toxic industrial material detection and identification, 580–581
Development of chemical weaponry
early chemical warfare agents (table), 116
early history, 116–117
1920s, 118–119
1930s, 119–120
1940s, 120
1950s, 120
1960s, 120–122
1970s, 122–124
1980s, 124–125
World War I, 117–118
World War II, 120
Dexanabinol
mechanism of action, 229–230
soman-induced seizure-related brain damage treatment, 229–230
DFP. *See* Diisopropyl fluorophosphate
DHS. *See* US Department of Homeland Security
Diagnostics
archived human samples from past exposure incidents and, 692–693
biomonitoring, 692
containers for shipping, 740
cyanide poisoning, 731–734
documentation for containers, 740
far-forward field settings and, 693
labeling specimens, 740
lewisite exposure, 728–731
method overview, 692–693
nerve agents, 693–706

packaging specimens, 740
phosgene exposure, 734–738
preparing, shipping, and storing specimens, 740–741
sample considerations, 739–741
sulfur mustard exposure, 706–728
3-quinuclidinyl benzilate, 738–739
Dianisidine chlorosulphonate
development and use of, 13–14, 79
Diazepam
anticonvulsive therapy, 189–190, 316
arrhythmia treatment, 179
brevetoxin intoxication treatment, 630
Convulsive Antidote, Nerve Agent injector for, 189–190
incapacitating effects, 420
pediatric population and, 664
severe nerve agent exposure and, 193, 194, 223, 244, 316, 520
soman-induced seizure-related brain damage treatment, 227–228, 230, 231–232
Dibenz*[b,f]*-1,4-oxazepine
acute effects, 467
characteristics of PS, CN, DM, and CR (table), 458–459
chemical structure (figure), 467
clinical effects, 467–469
deployment methods, 467
initial deployment of, 442
long-term effects, 468–469
nonmilitary uses, 342
physical characteristics, 467
physiological effects, 467
severe medical complications, 468–469
Dichlorethylsulphide. *See* Mustard agent
Dicobalt edetate. *See* Cobalt EDTA
Diglutathionyl dithiocarbonate. *See also* Glutathione
chemical structure (figure), 735
phosgene exposure and, 735–736
Diisopropyl aminoethanethiol
VX nerve agent assays and, 695
Diisopropyl fluorophosphate
bioscavenger use on, 250
British research on, 48
electroencephalographic effects, 321
toxicity of, 48
Diisopropyl phosphorofluoridate. *See* Sarin
blood cholinesterase inhibition and, 164–165
electroencephalographic effects, 176–177
insecticide use, 158–159
Diller, W.F.
phosgene research, 735
Dimercaprol. *See* British antilewisite
Diphenylaminearsine
acute effects, 465–466
characteristics of PS, CN, DM, and CR (table), 458–459
chemical structure (figure), 464
clinical effects, 465–466
deployment of, 464
development of, 442, 464
incapacitating dose, 465
incapacitating effects, 416
long-term effects, 466
mortality from, 465
physical characteristics, 464
physiological effects, 464
severe medical complications, 466
Diphosgene. *See* Chloropicrin
Dissociative anesthetics. *See also specific agents*
description and incapacitating effects, 419–420
Ditran
incapacitating effects, 426
Dizocilpine
soman-induced seizure-related brain damage treatment, 227–228
toxic effect of, 228
DM. *See* Diphenylaminearsine
DNA. *See* Deoxyribonucleic acid
DoD. *See* US Department of Defense
Domankevitz, Y.
mustard agent injury treatment, 285
Domestic preparedness
chemical preparedness programs and initiatives, 766–767
Chemical Security Analysis Center, 767
Chemical Stockpile Emergency Preparedness Program, 766–767
DoD roles, 758–761
DoD support to civil authorities, 761–764
effective information flow and, 754
emerging threats, 754
exercises, 766–767, 769–770
federal emergency response plan (figure), 762
"incident command system" and, 754
Laboratory Response Network, 765–766
local responses, 754
military healthcare role, 754, 764
National Bio-Defense Analysis and Countermeasure Center, 767
national civilian preparedness, 1990-2001, 754–755
National Disaster Medical System, 765
national preparedness programs and initiatives, 765–766
"120 Cities Program," 755
organizational outline for incident management command (figure), 757
overview of the initial federal involvement under the Stafford Act (figure), 760
post-September 11, 2001, 755–758
state and regional authorities and, 754
Strategic National Stockpile, 765
training and education, 767–770
Donepezil
Alzheimer's disease treatment, 158
Dorandeu, F.
ketamine research, 230
Doughty, John
chemical warfare proposals, 11–12
Downey, Maj. Fairfax
How to Tell the Gases poem, 41
DPIA. *See* Dry powder inhaler atropine
Drager-Tubes industrial detectors, 580–581
Drasch, G.
tissue sample analysis of mustard agent exposure, 726
urine sample analysis for mustard agent exposure, 710, 715–716
Drones
nerve agent delivery, 122
Dry decontaminants
animal studies, 534, 536
description, 534
examples of, 536
M291 skin decontamination kits, 533, 536, 581
water issues, 546
Dry powder inhaler atropine
development of, 652
Dugway Proving Ground, UT
open-air test of lethal chemical agents, 123
sheep-kill incident, 59
Durham, D.

status epilepticus treatment, 231
Durham, W.F.
organophosphate insecticide exposure research, 319
Dynport Vaccine Company
plasma-derived human butyrylcholinesterase production, 653

E

Easton, D.F.
mustard agent exposure research, 313
Ecstasy. *See* 3,4-methylene-dioxymethylamphetamine
Eddleston, M.
atropine treatment research, 184
Edgewood Arsenal, MD
Chemical Warfare Service and, 44, 117
incapacitating agent research, 414, 422–424, 425–426, 463–464, 466, 467
mustard agent production, 119
phosgene production, 119
post-World War I chemical training and research, 103
shell-filling plants, 117
3-quinuclidinyl benzilate research, 422–424
2-chlorobenzylidene malononitrile research, 450
EEG effects. *See* Electroencephalographic effects
Egypt
ancient use of toxic smoke, 10
Yemen Civil War and, 57–58, 341
Yom Kippur War and, 61
Eisenhower, Pres. Dwight D.
incapacitating agent research and, 414
Eldad, A.
mustard agent injury treatment, 284
Electroencephalographic effects
nerve agent exposure, 176–177, 321–322
organophosphate insecticide exposure, 321
three-stage changes, 177
Electrometric ChE assay
description and development of, 704
ELISA. *See* Enzyme-linked immunosorbent assay
Ellman assay
cholinesterase analysis, 702
Elsayed, N.M.
mustard agent research, 265
EMPA. *See* Ethyl methylphosphonic acid
Employment of Chemical Agents, Field Manual 3-10, 136
Enzyme debridement
mustard agent injury treatment, 284–285
Enzyme-linked immunosorbent assay
mustard agent exposure, 718, 721, 723
phosgene exposure, 738
Enzymes. *See* Bioscavengers
EPA. *See* US Environmental Protection Agency
Eq BChE. *See* equine serum butyrylcholinesterase
Equine serum butyrylcholinesterase
bioscavenging use, 245, 246
Equipment decontamination
M295 equipment decontamination kits, 582
M17 lightweight decontamination system, 583
M100 sorbent decontamination system, 582–583
Erbium:yttrium-aluminum-garnet laser ablation
mustard agent injury treatment, 284
Er:YAG. *See* Erbium:yttrium-aluminum-garnet laser ablation
Erythrocyte cholinesterase
gender differences in activity of, 164
physiological role, 164
relation of effects of nerve agent exposure to erythrocyte cholinesterase activity (table), 166
Ethiopia. *See* Italian-Ethiopian War
Ethyl bromoacetate tear gas
World War I and, 12–13
Ethyl iodoacetate tear gas
World War I and, 13
Ethyl methylphosphonic acid
VS nerve agent assays and, 695
Ethyl-S-diisopropylaminoethyl methylphosphonothiolate. *See* VX nerve agent
Explosive release of chemical weapons. *See also specific systems, i.e., Cluster bombs*
description, 132
droplet release, 132–133
vapor release, 132, 134
Exposure routes of nerve agents. *See also specific agents*
definitions of C*t*, LCt_{50}, and LD_{50} (exhibit), 168
dermal exposure to liquid, 169–170, 185–186, 244
effects of dermal exposure to liquid nerve agents (table), 169
effects of exposure to nerve agent vapor (table), 169
inhalational exposure to vapor, 168–169, 185, 244
Eyes
atropine treatment and, 191–192
chloropicrin effects, 457
chronic eye disease, 314
corneal damage, 274, 314
dibenz*[b,f]*-1,4-oxazepine effects, 468
dilute hypochlorite and, 537
dim vision, 171–172
diphenylaminearsine effects, 466
eye pain, 172
incapacitating agent effects, 442, 471
irrigation of, 277, 287
lewisite exposure effects, 293
light reduction, 171–172
mustard agent exposure effects, 274–275, 278, 290, 312, 667, 670, 672
mustard agent injury treatment, 287, 288
nerve agent exposure effects, 170–172
oleoresin capsicum effects, 455
1-chloroacetophenone effects, 461, 463
palytoxin effects, 619, 621
phosgene oxime exposure effects, 295
recovery from injury to, 274, 278
topical antibiotics for, 287, 288
transient vision loss, 287
2-chlorobenzylidene malononitrile effects, 448, 451–452
visual acuity, 172

F

Fabrizi, L.
phosgene research, 737
FBI. *See* Federal Bureau of Investigation
FBS AChE. *See* Fetal bovine serum AChE
FDA. *See* US Food and Drug Administration
Federal Bureau of Investigation
counterterrorism plans, 128
homeland security role, 755
oleoresin capsicum research, 443
riot control agent use to attack the Branch Davidian compound in Waco, TX, 125
terrorist plot to release chlorine gas at Disneyland and, 657
Federal Emergency Management Agency
Chemical Stockpile Emergency Preparedness Program role, 766–767
counterterrorism plans, 128
formation of, 755
state and regional coordination and, 759
Federal Response Plan

assignment of specific emergency support functions, 755
FEMA. *See* Federal Emergency Management Agency
Fentanyl
description and incapacitating effects, 419
summary of BZ and fentanyl derivatives (exhibit), 429
use by Russia in the Chechen hostage situation, 3, 65, 107, 413, 419
Fetal bovine serum AChE
bioscavenging use, 245, 246
Fidder, A.
blood sample analysis for mustard agent (figure), 723
lewisite exposure research, 728
organophosphorus compound research, 699
urine sample analysis for mustard agent, 711, 713
Field management of chemical casualties. *See also* Treatment of incapacitating agent exposure; Treatment of mustard agent exposure; Treatment of nerve agent exposure; Treatment of toxic industrial chemical exposure
attack measures, 494–495
"buddies" and, 486
casualty decontamination (figure), 502
casualty number and agent characteristics and, 496
civilian perspective, 492–493
cold zone, 500, 506
comparison of military battlefield and civilian casualty care and decontamination (table), 501
comparison of taxonomy of care capabilities with levels (echelons) of care particular to chemical casualty management (table), 488–489
core principles, 486
decontamination area, 505
decontamination equipment, 497
decontamination levels, 500
detailed example of the layout of a patient decontamination site (figure), 504
early control point and arrival area, 503–504
evacuation corridor, 500
force health protection description, 486
hazardous materials (HAZMAT) response teams and, 492–493
hazardous waste operations and emergency response training and, 515
HAZMAT incident medical treatment site setup (figure), 503
health service support description, 486
hot line, 505
hot zone, 498–499, 501
integration of military support into civilian homeland response, 493–494
key objectives, 495
land-based forces, 487–491
local responses, 492–493
medical equipment and supplies needed, 497–498
medical management process, 494–506
military management concepts in the civilian setting, 500–502
minimal decontamination procedures based on agent characteristics (table), 498
National Incident Management System, 492
National Response Plan, 492
national site setup and control zones for a hazardous materials site (figure), 515
patient processing, 502–506
personnel requirements, 495–497
pillars of force health protection (figure), 487
postattack, or recovery, measures, 495
preattack measures, 494
rapid and effective response capability, 486
sea-based forces, 491–492
service-specific operations, 487–492
taxonomy of care capabilities (figure), 490
terrorist attack capabilities, 493–494
triage and treatment area (cold zone), 506
triage area (warm side), 504–505
vapor control line, 505
warm zone, 499–500, 504–505
wet-bulb globe temperature and, 495–496
work-rest cycles and water consumption (without protective ensemble) (table), 497
work-rest cycles for workers, 495–496, 542
worker fitness level and, 496–497
zones of contamination, 498–500, 543
Field Management of Chemical Casualties Handbook
mustard agent treatment, 670
Filbert, M.G.
dexanabinol research, 229
Fisher, PFC David Allen
exposure to mustard agent during the Persian Gulf War (exhibit), 107
Fiske, Maj. Norman E.
Italian-Ethiopian War observation report, 45
520th Theater Army Medical Laboratory
field-forward assays for chemical agent exposure, 693
Florida
paralytic shellfish poisoning and, 624
Flumazenil
incapacitating effects, 420
Fluoxetine
incapacitating effects, 421
Foch, Marshal Ferdinand
Champagne-Marne defensive and, 30
Meuse-Argonne campaign and, 33
Ford, Pres. Gerald
incapacitating agent use and, 443
Foroutan, Syed Abbas
chemical agent exposure in children and, 656
nerve agent and mustard agent treatment research, 184, 195–196
patient thorough decontamination research, 540, 547
Foulkes, Maj. Gen. Charles H.
effectiveness of gas as a weapon, 79
4-dimethylaminophenol
cyanide poisoning treatment, 395–396
4-DMAP. *See* 4-dimethylaminophenol
France. *See also specific battles and battle sites*
Berber war, 42–43
chemical warfare use during World War I, 12–21
cyanide use during World War I, 373
hydroxocobalamin treatment for cyanide poisoning, 396, 676
incapacitating agent use, 443
weaponizing of phosgene, 341
Franco-Prussian War
cyanide use, 373
Frandsen, A.
dantrolene research, 228
Franzblau, A.
2-chlorobenzylidene malononitrile research, 452
Free radical scavengers
neuroprotectant use, 232
French, M.C.
dibenz*[b,f]*-1,4-oxazepine research, 467
Fricke,
cyanide poisoning treatment, 396
Fries, Maj. Gen. Amos A.
chemical training for soldiers and, 104
Chemical Warfare Service and, 43–44
Gas Service command, 22, 89–90

mustard agent and, 20
Fujikawa, D.G.
ketamine research, 230
Fuller, Maj. Gen. J.F.C.
Italian-Ethiopian War observation report, 46

G

G8 Global Partnership against Proliferation of Weapons and Materials of Mass Destruction
Russia's elimination of chemical weapons and, 144
G-series nerve agents. *See also specific agents*
categorization of (exhibit), 47
World War II use of, 3
GA. *See* Tabun
Gacyclidine
soman-induced seizure-related brain damage treatment, 230
Galanthamine
Alzheimer's disease treatment, 158
Gangliosides
mechanism of action, 227
soman-induced seizure-related brain damage treatment, 227
Gas chromatography
blood sample analysis for mustard agent exposure, 721, 723, 725, 726
combined with liquid chromatography for mustard agent assays, 711, 713
lewisite exposure, 728
nerve agent assays and, 695, 699
sample preparation methods for the gas chromatographic-mass spectrometric analysis of sulfur mustard adducts to blood biomolecules (exhibit), 724–725
sample preparation time, 693
urine sample analysis for mustard agent, 710, 716–717, 718
USAMRICD research, 693
use with MS, 692, 693
"Gas fright" syndrome
description, 82
Gas masks. *See also* Respirators
activated charcoal use in, 561
butyl rubber and, 562, 563
canisters for, 561
chemical destruction of the agent and, 561
composition of, 562
dead space and, 563
development of, 18
developmental objectives, 563
early types, 80
effectiveness against chlorine and phosgene, 19
effectiveness against mustard agent, 21
faceblanks for, 563
"hypo helmets," 561
joint service general purpose masks, 563
M17 series, 561
modern design features, 561–562
nose cups for, 563
original design features, 561
perfluorocarbon rubber and, 562
silicone rubber and, 562, 563
types of devices (figure), 84
use of for children, 657
voicemitters, 562
Gastrointestinal tract
brevetoxin effects, 630
chloropicrin effects, 457
dibenz*[b,f]*-1,4-oxazepine effects, 468
diphenylaminearsine effects, 466
mustard agent exposure effects, 275–276, 288, 290, 670, 672
oleoresin capsicum effects, 455
palytoxin effects, 619
2-chlorobenzylidene malononitrile effects, 452
Gay-Lussac, Joseph Louis
cyanide research, 373
GB. *See* Sarin
GC. *See* Gas chromatography
GD. *See* Soman
Gender factors
butyrylcholinesterase activity, 164
erythrocyte cholinesterase, 164
Geneva Protocol
chemical weapons provisions, 57, 61, 136–137, 341, 413
development of, 136–137
United States ratification of, 60, 137
weakness of, 137
Genovese, R.F.
equine serum butyrylcholinesterase research, 249
Germany. *See also specific battles and battle sites*
airplane gas attacks during World War I (exhibit), 26
chemical warfare use during World War I, 12–21, 79–82, 341, 413
chlorine gas attacks, 12, 14–18
experimental testing of chemical and biological warfare agents in concentration camps, 105, 157
failure to use chemical weapons in World War II, 48–50, 157, 262, 413
mustard agent attacks, 2–3, 15, 18, 20–21, 25–26, 83, 261–262
nerve agent production, 48, 156
nerve agent use in World War II and, 3, 413
phosgene attacks, 19–20
phosgene oxime production, 294
Russia's elimination of chemical weapons and, 145
secret development of nerve agents, 46
trichloromethyl chloroformate attacks, 20
Zyklon B use in Nazi concentration camps, 15, 51, 105, 373, 397, 656
Gershon, S.
organophosphate insecticide exposure research, 319, 320
GF. *See* Cyclosarin
Giesbrecht, G.G.
hypothermia research, 548
Gilchrist, Col. Harry L.
chemical training for soldiers and, 103
Chemical Warfare Service leadership, 90–91, 97
plan of a division in action for chemical warfare training purposes (figure), 86
"Symptomology, Pathology and General Treatment of Gas Cases," 91
GK-11. *See* Gacyclidine
Glass, Col. Albert
incapacitating agent treatment research, 430
Glaucoma
carbamate treatment, 158
Gloves
chemical protective glove set, 573–574
decontamination of chemical casualties and, 539
joint service lightweight integrated suit technology block 2 glove upgrade, 574
Glutathione. *See also* Diglutathionyl dithiocarbonate
description, 735
mechanism of lung injury, 352–353
mustard agent reactions with, 265, 708, 711, 717–718
phosgene exposure and, 735–736, 738
reaction pathway of glutathione (figure), 712
Glycolates. *See* Anticholinergic deliriants
GM1 monosialoganglioside

soman-induced seizure-related brain damage treatment, 227
Goebbels, Paul Joseph
views on chemical warfare, 49
Gongwer, L.E.
2-chlorobenzylidene malononitrile research, 449
Goodman, Ephraim
incapacitating agent research, 412–413, 425, 427
Graebe, Carl
1-chloroacetophenone invention, 442
Graham, J.S.
mustard agent injury treatment, 284, 285, 671
wound debridement of chemical casualties research, 539
Graniteville, South Carolina
accidental release of chlorine, 131, 145, 548
Grant, Gen. Ulysses S.
chemical weapon use and, 12
Gray, P.J.
2-chlorobenzylidene malononitrile research, 451–452
Great Britain. *See also specific battles and battle sites*
chemical warfare use during World War I, 12–21
dibenz*[b,f]*-1,4-oxazepine use in prisons, 467
excerpt from "Take Me Back to Dear Old Blighty!" (exhibit), 89
nerve agent research, 48
plans for gas warfare during World War II, 52
Royal Army Medical Corps, 85–89
Russia's elimination of chemical weapons and, 145
six chlorine-phosgene cloud attacks: British casualties December 1915-August 1916 (table), 83
VX nerve agent synthesis, 157
Greece
ancient use of incapacitating agents, 412
ancient use of toxic smoke, 10, 78, 341
cyanide use, 373
Greek fire and flaming concoctions, 11, 78, 341
"Green cross." *See* Chloropicrin
Grignard, Francois Auguste Victor
chemical weapons developed by, 15
Growth factors
mustard agent injury treatment, 285–286
Gruenthal, M.
dantrolene research, 228
GSCOSG. *See* Diglutathionyl dithiocarbonate
GSH. *See* Glutathione
Guide for the Selection of Chemical Agent and Toxic Industrial Material Detection Equipment for Emergency First Responders, 581
"Gulf War" syndrome
description, 64
Gutentag, P.J.
2-chlorobenzylidene malononitrile research, 449, 450
Guthrie sulfur mustard synthesis, 260

H

Haber, Fritz
comments on the importance of chemical warfare, 41
development of chlorine gas as a weapon, 14, 15, 80
Second Battle of Ypres and, 14, 15
Zyklon B development, 15, 51
The Hague
court of arbitration, 136
Haig, Gen. Douglas
Battle of Loos and, 18
Haig, Secretary of State Alexander M., Jr.
"Chemical Warfare in Southeast Asia and Afghanistan," 62
Hair sample analysis
mustard agent, 726
Halothane
pediatric population and, 667
HAPSITE Smart Chemical Identification System
description, 544
Harel, M.
human paraoxonase 1 research, 251
Harrigan, A.
Armed Forces Chemical Journal article, 57
Hart, B.H. Liddell
Italian-Ethiopian War observation, 46
Hassan, Capt. Kifah Ali
Iraq's attacks on the Kurds and, 126
Hay, Alistair
Russia's use of an incapacitating agent against Chechens, 413
HC smoke. *See* Hexachloroethane smoke
HCN. *See* Hydrogen cyanide
HD. *See* Mustard agent
Health Service Support in a Nuclear, Chemical and Biological Environment (FM 4-07.7), 609
Health Service Support in a Theater of Operations, 512
Heart rate
effects of nerve agent exposure, 180
Heat injuries
acclimatization and, 604
heat stress physiological monitoring for chemical agent workers, 603–604
individual protective ensemble and, 528, 541–543, 569
moderating strategies, 603
training and, 603
Heat stroke
differential diagnosis of incapacitating agent intoxication, 428
Hebb seizure-related brain damage research, 226
Hefazi, M.
mustard exposure research, 313
Heinrich, U.
2-chlorobenzylidene malononitrile research, 450
Hellreich, A.
2-chlorobenzylidene malononitrile research, 450
Hematologic effects
paralytic shellfish poisoning, 626
Hemodialysis
saxitoxin treatment, 627
tetrodotoxin treatment, 627
Henderson, Dr. Yandell
toxic gas research, 89
Henderson, NV
accidental release of chlorine, 131
Hesse, isolation of physostigmine, 46, 156
Heston, W.E.
mustard exposure research, 313
Hexachloroethane smoke
composition of, 358
toxic effects of exposure, 324, 327, 358–359
Higginbottom, R.
dibenz*[b,f]*-1,4-oxazepine research, 467, 468
Hill, A.R.
2-chlorobenzylidene malononitrile research, 452
Himsworth, H.
2-chlorobenzylidene malononitrile research, 452
Historical background
chemical attacks involving children, 656–657
chemical terrorism, 125–130
chemical warfare capabilities, 130–136
chemical weapons agreements, 136–145
cyanide use, 372–373
development of chemical weaponry, 116–125
early military uses of toxins, 10–11, 78–79
incapacitating agents, 412–414, 443
medical management of chemical casualties, 78–109

nerve agent use, 156–158
1920s, 42–45
1930s, 45–47
1950s, 54–56
1960s, 56–60
1970s, 60–62
1980s, 62–63
1990s, 63–65
21st century, 65–66
US Civil War, 11–12
World War I, 12–42
World War II, 48–54
History of the Peloponnesian War (Thucydides), 10, 78
Hitler, Adolf
chlorine gas attack and, 17, 49, 157
Germany's failure to use chemical weapons in World War II and, 49, 157, 413
HN-1. *See* Nitrogen mustard
Hoch, Dr. Paul
lysergic acid diethylamide research, 413
Hoffmann, Albert
lysergic acid diethylamide research, 413
Holland, P.
1-chloroacetophenone research, 463
Holmes, J.H.
organophosphate insecticide exposure research, 319, 320
Homatropine
eye pain and, 192
topical application of, 190
"Honest John" rockets
nerve agent delivery, 122
Hospitals
decontamination shelters, 545–546
Hospital Management of CBRNE Incidents Course, 769
M22 automatic chemical agent detector and alarm and, 577
patient thorough decontamination areas, 529
How to Tell the Gases (Downey), 41
HS. *See* Mustard agent
H_2S. *See* Hydrogen sulfide
Hu, H.
2-chlorobenzylidene malononitrile research, 452
HU-211. *See* Dexanabinol
Hu PON1. *See* Human paraoxonase 1
Human paraoxonase 1
mutation designs, 250–251
Hun stoffe. *See* Mustard agent
Hup A. *See* Huperzine A
Huperzine A
compared with physostigmine, 704
mechanism of action, 705–706
pretreatment with, 704–706
red blood cell and acetylcholinesterase protection studies using pyridostigmine bromide and huperzine A after ex-vivo exposure to soman (table), 705
Hurricane Katrina
National Response Plan and, 492
Huxley, Aldous
"psychedelic" definition and, 416
Hydrocyanic acid
US troop training and, 53
Hydrogen cyanide. *See also* Cyanide poisoning
discovery of the properties and composition of, 116
introduction of, 18
nonmilitary uses, 342–343
treatment for inhalation of, 353–354
volatility of, 134, 136
Hydrogen sulfide
properties of, 343–344
Hydrolysis compound assays
analytical methods, 695
analytical methods for assay of nerve agent hydrolysis products (table), 697
application to human exposure, 695–698
hydrolysis pathway of sarin, soman, and cyclosarin (figure), 696
methods used to confirm human exposures to nerve agents via assay of hydrolysis products (table), 698
Hydroxocobalamin
cyanide poisoning treatment, 385, 390, 393, 396–397, 651, 676
properties, 396–397
side effects, 396
Hypochlorite
decontamination of chemical casualties and, 537
pediatric casualties and, 677
Hypothermia
decontamination issues, 548–549, 677
pediatric population and, 661
stages and symptoms of (table), 548

I

Ibuprofen
phosgene inhalation treatment, 354
ICAMs. *See* Improved chemical agent monitors
ICG. *See* Indocyanine green fluorescence imaging
IEDs. *See* Improvised explosive devices
Improved chemical agent detectors
false readings and, 576
simplicity of operation, 576
Improved chemical agent monitors
cold weather operation of, 550
description, 544, 576
effects on decontamination, 531
Improvised explosive devices
development and use of, 130, 145
toxic industrial material used in, 580
Incapacitating agents. *See also specific agents*
anticholinergic deliriants, 422–425
antipsychotic drugs, 420
armed robots and, 415
auditory method of incapacitation, 414
cannabinoids, 418
characteristics of PS, CN, DM, and CR (table), 458–459
chemical methods of incapacitation, 415–425
chloropicrin, 443, 455–457
common features, 442
controversy over using, 431–432
conventional wounds contaminated with, 523
decontamination, 469–471
delivery systems, 122
diagnosis of syndromes caused by, 428–430
dibenz*[b,f]*-1,4-oxazepine, 442, 467–469
differential diagnosis for (table), 429
diphenylaminearsine, 443, 464–466
dissociative anesthetics, 419–420
factors in decisions to employ, 412, 415
FBI's use to attack the Branch Davidian compound in Waco, TX, 125
features of, 133–134
goal of, 412
higher integrative or cognitive functions and, 415
history and modern development of, 412–414, 443
indole-based psychedelics, 416–418
irritants, nausea-producing agents, and toxins, 416
Kratschmer reflex and, 442

legal barriers to acceptance as weapons, 431
lethality of, 415
medical care issues, 469–472
medical management, 430
methods of incapacitation, 414–425
microwave effects, 414
mortality from, 442
nerve agents, 416
neuropeptides and neuromodulators, 420–422
new developments and future use, 472
nonchemical methods of incapacitation, 414–415
nonlethal land mines, 415
nonmilitary uses, 342
oleoresin capsicum, 443, 452–455
olfactory devices, 414–415
1-chloroacetophenone, 443, 460–464
opioids, 418–419
personal protection, 469
phenethylamine-based psychedelics, 418
physiological responses to, 348, 472–473
police department use, 443
policy perspective on, 431–432, 443
production of, 59
psychoactivity manifestations, 415
purpose of, 442, 472
research on, 55–56
safety margin variations, 415
safety of, 442
safety of glycolates, 427
sedative hypnotics, 418
stimulants, 418
summary of BZ and fentanyl derivatives (table), 429
tranquilizers, 420
treatment, 425–426, 471–472
triage considerations, 520, 521, 522, 523
2-chlorobenzylidene malononitrile, 416, 443, 444–452
use of light, 414
vesicants, 416
India
accidental release of methyl isocyanate in Bhopal, 131, 134, 326, 347
Individual chemical patient resuscitation devices
composition and uses of, 587–588
description, 587
Individual protective ensemble
barrier creams and, 531
cold weather and, 549
heat injuries and, 528, 541–543
M20 simplified collective protection equipment and, 586
name and job markings for, 547
removal of, 547
Individual protective equipment
decontamination personnel requirements, 543–544
protective clothing, 569–574
psychological factors in the use of, 575
respiratory protection, 561–569
toxic industrial material and, 580
training in the use of, 575
vapor penetration of, 543–544
Individuals with physical or mental disabilities
decontamination issues, 551
Indocyanine green fluorescence imaging
mustard agent injury assessment, 283
Indole-based psychedelics. *See also specific agents*
experiments using, 3, 56
"psychedelic" definition, 416
Industrial chemicals. *See* Inhalational injury from toxic industrial chemicals; Toxic industrial chemicals; Toxic industrial materials; *specific chemicals*
Infants and children. *See also* Medical management of chemical toxicity in pediatrics
accidental exposures to mustard agent, 263
cyanide poisoning and, 389–390, 394
decontamination issues, 550–551
treatment of nerve agent exposure, 195
2-chlorobenzylidene malononitrile ingestion and, 452
Inhalational exposure to nerve agent vapor. *See also* Pulmonary system
atropine treatment, 185
compared with dermal exposure, 169–170
effects of, 168–169
long-term health effects, 324–327
severe exposures, 168–169
Inhalational injury from toxic industrial chemicals
airway compartments (figure), 355
arterial blood gases and, 360
biochemical responses, 351–353
bronchoalveolar lavage and, 361
carbon dioxide levels and, 361
cell membrane destruction, 350
centrally acting agents, 355–356, 359
chemicals that act on both the central and peripheral airways, 359
chest radiographs and, 360
clinical presentation and diagnosis, 355–361
decreased body weight and, 348
determination of the damaged compartment, 340
diagnostic tests, 360–361
"dry land drowning," 357
gaseous ammonia effects at various concentrations (table), 355
general mechanisms of toxic gas exposure (figure), 347
general schema for the study of acute and chronic lung injury (figure), 352
glutathione and, 352–353
inflammatory pathways, 350–351
long-term health effects, 354–355, 365
main inflammatory agents involved in acute lung injury, their source and action (table), 351
mechanism of injury, 340, 355, 356–357
mechanism of lung injury and repair (figure), 349
mechanisms of lung injury of gaseous respiratory irritants (table), 346
mechanistic effects, 346–353
medical management, 361–365
pathophysiological effects, 348–350
patient transport and, 365
peripherally acting agents, 356–360
physiological responses, 347–348
pulmonary capillary wedge pressure and, 361
pulmonary function tests and, 360–361
specific inhaled toxic-gas-induced effects and their treatments, 353–355
ventilation/perfusion scans and, 361
Insecticides. *See also* Organophosphate insecticides
organophosphorus compounds used as, 158–159, 316
Institute of Medicine
study on the effects of mustard agent and lewisite exposure, 312–313, 314, 315, 316
Interagency for Research on Cancer
classification of mustard as a human carcinogen, 315–316
Intermediate syndrome
nerve agents and, 318–319
organophosphate insecticides and, 318–319
International Classification of Epileptic Seizures

status epilepticus definition, 223
International Red Cross
Yemen Civil War and, 58
IPE. *See* Individual protective ensemble
Ipratropium
brevetoxin intoxication treatment, 631
Iran
case history: nerve agent exposure in Nazhmar, Iran (exhibit), 662
Iran-Iraq War
assay techniques for mustard exposure, 692–693, 713, 715, 716, 721
chemical weapons use, 3, 62–63, 106, 157–158, 195–196, 260, 312, 314, 373, 656
mustard agent and, 262–263, 279, 288, 314, 315, 656, 667
Iraq. *See also* Iran-Iraq War; Persian Gulf War
accidental exposure of two US soldiers to sarin in Baghdad, 157–158, 168, 195, 197
case history: mustard gas exposure in 14 children and teenagers from Halabja, Iraq (exhibit), 667
chemical weapon stockpiles, 157, 312
clinical cases of mustard exposure from Mofid Medical Center following the Halabja, Iraq, attack on March 17, 1988 (exhibit), 668–669
clyclosarin synthesis, 157
cyclosarin production, 202
Operation Iraqi Freedom and, 65–66, 130
stocks of sarin and VX, 202
use of chemical weapons against the Kurds, 63, 65, 106, 126
use of 3-quinuclidinyl benzilate during the Persian Gulf War, 413
Irving, Capt. T.C.
report on field sanitation, 84–85
Isoproterenol
phosgene inhalation treatment, 354
Isosorbide dinitrate
palytoxin intoxication treatment, 622
Israel
Arab-Israeli Six-Day War, 58
deaths from improper use of gas masks, 657
midazolam use for status epilepticus and, 664
possible use of DM against Palestine, 443
Yom Kippur War, 61
Italian-Ethiopian War
chemical weapons role, 45–46, 137, 262
Italy
Centro Chemico Militaire, 43
cyanide plot against the US Embassy, 128
early use of poison projectiles, 11
Italian-Ethiopian War, 45–46
mustard agent disaster at Bari, 21, 53, 105, 262
Russia's elimination of chemical weapons and, 145

J

Jaeger, Private August
warning of a German gas attack, 80
Jakubowski, E.M.
nerve agent research, 699
skin sample analysis for mustard agent exposure, 726
urine sample analysis for mustard agent exposure, 716
Jane's NBC Protection Equipment, 561
Japan
accidental palytoxin poisoning, 620
Aum Shinrikyo sarin attacks, 4, 125, 127–128, 158, 178, 181–182, 193, 196–197, 223, 244, 316, 317, 321, 492, 518, 540, 657, 695–696, 699, 754
chemical weapon production, 48
incapacitating agent use, 443
invasion of China in 1937, 46, 262
paralytic shellfish poisoning and, 624
Japanese puffer fish. *See* Tetrodotoxin
Jobst
isolation of physostigmine, 46, 156
Johnston Island
demilitarization of chemical agents, 142, 157
Joint Combat Developer
role in chemical weapon management, 4
Joint Commission on Accreditation of Healthcare Organizations
disaster and medical response to mass casualty events, 492, 493–494
training and education for domestic preparedness and, 767
Joint Program Executive Office
role in chemical weapon management, 4
Joint Program Executive Office for Chemical Biological Defense
medical identification and treatment systems joint product management office, 647–650
medical program management, 647
responsibilities, 646–647
Joint Project Management Office for Decontamination
Reactive Skin Decontamination Lotion and, 652–653
Joint Requirements Office for Chemical, Biological, Radiological, and Nuclear Defense
responsibilities, 646, 650
role in chemical weapon management, 4
Joint Science and Technology Office
responsibilities, 650
role in chemical weapon management, 4
Joint service general purpose masks
composition, 567
description, 563
M50 and M51 models, 567–568
sizes, 568
TIC filters, 568
Joint service lightweight integrated suit technology
block 2 glove upgrade, 574
description and composition of, 572
design of, 572–573
two versions of, 573
Joint service mask leakage tester
description, 564
fit and, 563, 564
key features, 565
Joint service personnel skin decontamination system
description and uses, 582, 652
Joint services lightweight standoff chemical agent detectors
description and uses, 579
Joint Test and Evaluation Executive office
role in chemical weapon management, 4
Joint Vaccine Acquisition Program
description, 4
responsibilities, 647
Jones, Jim
mass suicide of followers using cyanide, 374
Josse, D.
human paraoxonase 1 research, 251
JPEO. *See* Joint Program Executive Office
JPEO-CBD. *See* Joint Program Executive Office for Chemical Biological Defense
JSGPMs. *See* Joint service general purpose masks
JSLIST. *See* Joint service lightweight integrated suit technology
JSLSCADs. *See* Joint services lightweight standoff chemical agent detectors
JSMLT. *See* Joint service mask leakage tester

K

Kargin, Col. V.A.
capture of soman research documents, 51
Keeler, J.R.
interaction of pyridostigmine bromide with other commonly used battlefield medications, 201–202
Kemp, K.H.
2-chlorobenzylidene malononitrile research, 452
Kennedy, Pres. John F.
incapacitating agent research and, 414
Ketamine
adverse effects, 231
combined with diazepam, 230–231, 232
description and incapacitating effects, 419–420
dosage considerations, 230, 231–232
mechanism of action, 230
off-label use as a neuroprotectant, 231
soman-induced seizure-related brain damage treatment, 230–232
Kibler, A.L.
1-chloroacetophenone research, 462–463
Kiese, M.
cyanide poisoning research, 394, 395–396
"King of the war gases." *See* Mustard agent
Kirwin, W.E.
1-chloroacetophenone research, 462
Kishi, Y.
tetrodotoxin synthesis, 623
Kjellstrom, B.T.
mustard agent injury treatment, 284
Klasen, H.J.
enzyme debridement of mustard agent injuries, 284
Kling, A.
phosgene research, 736
Kluchinsky, T.A., Jr.
2-chlorobenzylidene malononitrile research, 447
Koenig, K.L.
summary of triage systems, 517
Kolokol-1. *See* Fentanyl
Kondritzer, Albert
3-quinuclidinyl benzilate research, 423
Konzo
cyanide exposure and, 323
Koplovitz, I.
memantine research, 228
Korean War
chemical weapons and, 54, 105
Korte, W.D.
skin sample analysis for mustard agent, 726
Krar, William
terrorist attack plan, 128–129
Krueger,
organophosphorus compound research, 156
Krutzsch, Walter
criticism of the Chemical Weapons Convention, 140–141
Kubic, V.L.
phosgene research, 736
Kuhn, Richard
soman discovery and synthesis, 48, 51, 157
Kukenthal, Hans
tabun research, 47
Kumar, P.
1-chloroacetophenone research, 460–461
Kurbegovic, Muharem. *See* Alphabet Bomber
Kurds
Iraqi use of chemical weapons against, 63, 65, 106, 126, 373, 656–657
Kuschner, W.G.
hexachloroethane smoke research, 327
Kuwait
Iraq's invasion of, 63–64

L

Laboratory Response Network
description and role, 765–766
reference laboratories, 766
sentinel laboratories, 766
Lacrimators. *See* Incapacitating agents
Lam, D.G.
mustard agent injury treatment, 285
Land mines
nonlethal types, 415
used in conjunction with military barrier systems, 135
VX nerve agent delivery, 120–121, 157
Lange, Willy
organophosphorus compound research, 47, 156
Larimer, E.
cold-weather protection of decontamination personnel, 549
Laser Doppler perfusion imaging
mustard agent injury assessment, 283
Lashley
seizure-related brain damage research, 226
LC. *See* Liquid chromatography
LDPI. *See* Laser Doppler perfusion imaging
League of Nations
Conference for the Supervision of the International Trade in Arms and Ammunition, 136–137
Leber hereditary optic neuropathy
cyanide exposure and, 323–324
LeGrand, Walter
gas chamber execution, 374
Lemercier, G.
nerve-agent-induced brain damage research, 223
Leven
physostigmine isolation, 46
Levin, H.S.
organophosphate insecticide exposure research, 320
Levine, R.A.
1-chloroacetophenone research, 463
Lewis, Capt. W. Lee
lewisite named for, 117, 292
Lewisite
additives for, 135
analysis of urine and blood samples, 728
antidote for, 291
application to human exposure, 728–731
biochemical mechanisms of injury, 292, 667
biomarkers for, 728
clinical effects, 292, 667
cold weather and, 548
compared with mustard agent, 261, 291
description, 728
diagnosis, 293
early production of, 3
Germany's experimental testing on human subjects in concentration camps, 105
Institute of Medicine study on the effects of mustard agent and lewisite exposure, 312–313, 314
Japan's use of against China, 46
laboratory tests, 293
"lewisite shock," 293
long-term effects, 294
mechanism of action, 136, 728
military use, 292

properties of, 292
published analytical approaches for the analysis of CVAA in urine (figure), 729
putative mechanism by which lewisite causes tissue damage (figure), 292
sample preparation methods for gas chromatographic/mass spectrometric analysis of CVAA (exhibit), 730
toxicity, 292
treatment, 293, 667
US production of, 117
Veterans Administration study on the effects of mustard agent and lewisite exposure, 312–313
Ley, Robert
views on chemical warfare, 49
LHON. *See* Leber hereditary optic neuropathy
Libya
increase in chemical weapon development, 65
use of chemical weapons against Chad, 63
Lidocaine
saxitoxin treatment, 627
tetrodotoxin treatment, 627
Limitation of Arms Conference
stockpiling of chemical weapons and, 44
Lindsay, C.D.
mustard agent injury treatment, 285
Liquid chromatography
blood sample analysis for mustard agent, 723, 725, 726
combined with gas chromatography for mustard agent assays, 711, 713
combined with mass spectrometry for mustard agent assays, 692, 713, 720–721, 723
nerve agent assays and, 695
phosgene, 737
urine sample analysis for mustard agent, 716–717, 718, 720–721
"Little John" rockets
nerve agent delivery, 122
Livens projectors
description, 118, 119
Long-term health effects
chloropicrin exposure, 457
cyanide poisoning, 387–389
dibenz*[b,f]*-1,4-oxazepine exposure, 468–469
lewisite exposure, 294
mustard agent exposure, 291, 312–316
nerve agent exposure, 177–179
oleoresin capsicum exposure, 455
1-chloroacetophenone exposure, 463–464
retrospective studies and, 313
toxic industrial chemical exposure, 354–355, 365
2-chlorobenzylidene malononitrile exposure, 452
Loos, Battle of
chlorine gas attacks, 18–19
Lorazepam
brevetoxin intoxication treatment, 630
LSD intoxication treatment, 417
nerve agent exposure treatment, 190, 223
Lott, Joseph
chemical warfare proposal, 12
LRN. *See* Laboratory Response Network
LSD. *See* Lysergic acid diethylamide
Ludendorff, Gen. Erich
Lys Defensive and, 26
Lund,
burn severity assessment, 282
Lundy, P.M.
VX nerve agent research, 529
Lung cancer
mustard agent exposure and, 313–314
Lungs. *See* Pulmonary system
Luten, Dr. Robert
Broselow-Luten system and, 681–683
Chemical Warfare Involving Kids Response Project and, 681
Lys defensive
chemical attacks, 26–27
Lysergic acid diethylamide
blood level assays, 417
Chemical Corps testing of, 416–417
historical background of research on, 413–414
mode of action, 417
physiological effects, 417, 428
research on effects of, 56
toxicity of, 417
treatment for intoxication by, 417
unique features of, 416
unpredictability of effects, 417–418

M

M22 automatic chemical agent detector and alarm
description, 544
description and uses, 577
M272 chemical agent water testing kits
description and detection limits, 577
M45 chemical-biological masks
description, 566
Land Warrior program and, 567
voicemitters, 566–567
M53 chemical-biological protective masks
audio frequency modifiers, 569
protective hoods, 568–569
sizes, 568
US Special Operations Command requirements, 568
M8 chemical detector paper
description and uses, 544, 575
M9 chemical detector paper
description and uses, 544, 575–576
M28 collective protection equipment
description and uses, 585
M295 equipment decontamination kits
description and uses, 582
M17 lightweight decontamination system
description and uses, 583
M41 protection assessment test system
description, 564
fit and, 563
M21 remote sensing chemical agent alarms
description, 578
placement of, 579
uses of, 579
M20 simplified collective protection equipment
description, 586
IPE and, 586
M291 skin decontamination kits
Ambergard resin and, 652–653
components, 536, 581
description, 533, 581
introduction of, 536
Reactive Skin Decontamination Lotion and, 536, 653
SERPACWA and, 652
M100 sorbent decontamination system
description and uses, 582–583
M256A1 chemical agent detector kits
description and uses, 576–577
detection limits, 577
M42A2 chemical-biological combat vehicle masks

description and uses, 566
M40A1 chemical-biological field masks
components, 565–566
composition of, 565
sizes, 565–566
voicemitters, 565
MacArthur, Gen. Douglas
comments on US chemical warfare policy, 44–45
Madden, J.F.
1-chloroacetophenone research, 463
Maddern
cyanide research, 373
Mafenide acetate
pediatric population and, 672
treatment of mustard agent injuries, 280, 281, 671–672
Malathion
blood cholinesterase inhibition and, 165
insecticide use, 158
MANAA. *See* Medical aerosolized nerve agent antidote
Manning, K.P.
mustard agent exposure research, 313
March, Chief of Staff Gen. Peyton C.
Chemical Warfare Service and, 43
Mark I kits
buddy administration of, 190
components, 651
FDA approval for, 651
nerve agent exposure treatment, 182–186, 188, 190, 192, 194, 518, 520–521, 523, 651–652
pediatric population and, 663, 683
treatment of children and, 195
Marrs, T.C.
dibenz*[b,f]*-1,4-oxazepine research, 468
hexachloroethane smoke research, 327
2-chlorobenzylidene malononitrile research, 449
Martin, L.J.
"apoptosis-necrosis continuum," 224
Mass spectrometry
basis for, 692
blood sample analysis for mustard agent exposure, 721, 725, 726
cholinesterase analysis, 701–702
combined with liquid chromatography for mustard agent assays, 713, 720–721
lewisite exposure, 728
mustard agent assays, 708, 716–717, 718, 720–721
nerve agent assays and, 695, 699
phosgene, 737
sample preparation methods for the gas chromatographic-mass spectrometric analysis of sulfur mustard adducts to blood biomolecules (exhibit), 724–725
sample preparation time, 693
Maxwell, D.M.
fetal bovine serum AChE research, 245
McBride, Capt. Lewis M.
rifling of the Stokes mortar barrel, 118
McCombie, Hamilton
diisopropyl fluorophosphate research, 48
McLean, M.J.
memantine research, 228
McLeod, C.G., Jr.
nerve-agent-induced brain damage research, 223
McNamara, B.P.
1-chloroacetophenone research, 460
2-chlorobenzylidene malononitrile research, 446–447, 449, 450
McNamara, Secretary of Defense Robert S.
Project 112 and Project 80 and, 56
MCU-2/P chemical-biological masks
description and uses, 566
MDMA. *See* 3,4-methylene-dioxymethylamphetamine
Meade, Capt. John
Italian-Ethiopian War observation report, 45–46
MEDCOM. *See* US Army Medical Command
Medical aerosolized nerve agent antidote
description, 651
nerve agent exposure treatment, 186, 192, 651–652
purpose of, 651–652
shelf life issues, 652
Medical chemical defense acquisition programs
acquisition manufacturing strategy, 649
acquisition process, 646
business and contracting strategy, 650
challenges, 650–651
compound purity and, 651
concept development (pre-milestone A activities), 647–648
current good manufacturing processes and, 649
intellectual property rights and, 649
joint vaccine acquisition program, 647
lifecycle management products, 651–652
manufacturing challenges, 651
medical chemical acquisition organizations, 646–647
medical chemical acquisition processes and concerns, 647–651
model for integrating pharmaceutical development, FDA regulatory, and the Department of Defense acquisition processes (figure), 648
operations and support phase, 649
production and deployment, 649
products in advanced development, 652–654
specific concerns, 650–651
status of, 651–654
sustainment programs, 652
system development and demonstration, 649
technology development and, 648–649
test and evaluation strategy, 649–650
transformational medical technologies initiative, 647
US Food and Drug Administration and, 646, 647, 648–653
Medical Defense Against Mustard Gas: Toxic Mechanisms and Pharmacological Implications, 265
Medical Identification and Treatment Systems
description, 4
Medical identification and treatment systems joint product management office
acquisition business and contracting strategy and, 650
advanced development of drugs and, 650
"animal rule" for drug product approval and, 647, 651
coordination with the technology base, 648
lifecycle management, 649
mission of, 647
production and deployment plans and, 649
responsibilities, 647
streamlining of acquisition, 650
technology development and, 648–649
Medical Management of Chemical Agent Casualties Handbook, 184
Medical management of chemical casualties. *See also* Medical management of chemical toxicity in pediatrics
Medical Management of Chemical and Biological Casualties Course, 763, 768
post-World War I, 103–107
pre-World War I, 78–79
projections for the future, 108
World War I, 79–102
Medical management of chemical toxicity in pediatrics
Broselow-Luten system: a systematic approach with color coding, 681–683

case history: mustard gas exposure in 14 children and teenagers from Halabja, Iraq (exhibit), 667
case history: nerve agent exposure in Nazhmar, Iran (exhibit), 662
challenges to, 657–661
Chemical Warfare Involving Kids Response Project, 681
clinical cases of mustard exposure from Mofid Medical Center following the Halabja, Iraq, attack on March 17, 1988 (exhibit), 668–669
color coding system, 681–683
decontamination equipment and treatment supplies, 661
dermatologic vulnerability, 659
developing a family emergency plan (exhibit), 680
effects of specific agents, 661–676
example of a pediatric-specific hospital emergency drug cache (table), 679
family emergency plan, 678, 680
general principles of chemical exposure, 657
history of chemical attacks involving children, 656–657
logistical time increase, 681–682
management of mild to moderate nerve agent exposures (table), 665
management of severe nerve agent exposure (table), 667
management of vesicant exposures (table), 671
managing pulmonary agent exposures (table), 674
metabolic vulnerability, 660
National Center for Disaster Preparedness, 683
neurobehavioral vulnerability, 660
neurological vulnerability, 659
organ maturity and, 660
pediatric signs of mustard exposure (table), 670
pediatric vulnerabilities and implications for clinical management (table), 658
plasma protein binding and, 659
preoperative care of children with nerve agent intoxication, 665, 667
preparing for a chemical event, 678–680
psychological impact, 678, 680
psychological vulnerability, 660
resources, 681–684
respiratory vulnerability, 659
steps involved in administering a dose of medication (figure), 682
strategies to help children cope with terrorist events (exhibit), 680
traumatic injury vulnerability, 660
uncooperative or nonverbal children, 678
unique vulnerabilities, 656
volume of distribution and, 659–660
volume status and, 659
Medical surveillance for chemical agent workers
diagram (figure), 598
factors determining the type and frequency of surveillance, 599
heat stress physiologic monitoring, 603–604
medical surveillance compared with personnel reliability, 599
periodic medical examinations, 600–601
potential exposure evaluations, 602
preplacement examinations, 599–600, 603–604
respirator clearances, 602
screening, 599
substance abuse and dependency screening, 602–603
termination examinations, 601–602
Meier, H.L.
PARP inhibitor treatment, 227
Memantine
Alzheimer's disease treatment, 228
pharmacokinetics of, 228
soman-induced seizure-related brain damage treatment, 228–229
Memorandum on Gas Poisoning in Warfare with Notes on its Pathology and Treatment, 90
Mendelson, J.A.
treatment of mustard agent injuries, 281
Mescaline
clinical effect research, 56
Metabolic system
cyanide poisoning and, 376
pediatric vulnerability to toxic agents and, 660
Metal fume fever
hexachloroethane smoke and, 327, 358
Metcalf, D.R.
organophosphate insecticide exposure research, 319, 320
Methemoglobin formers. *See also specific agents*
cyanide poisoning treatment, 383–384, 386, 390, 394–396
Methotrexate
similarity of mustard agent to, 313
Methyl isocyanate
accidental release of in Bhopal, India, 131, 134, 326, 347
Methylprednisolone
toxic industrial chemical exposure treatment, 363
Meuse-Argonne offensive
army-level gas hospitals, 97
chemical attacks, 33, 36
overview of (figure), 35
Spanish influenza and, 101
Meyer, Victor
mustard agent research, 117, 260
Michel, H.O.
electrometric ChE assay research, 704
Midazolam
brevetoxin intoxication treatment, 630
developmental concerns, 653
FDA approval issues, 653
nerve agent exposure treatment, 190, 223, 664
Military medicine. *See also* Medical management of chemical casualties
chemical accident and incident preparedness, 142–143
chemical weapon implications, 145–146
preparation for chemical attacks, 132
Minami, M.
sarin research, 695, 696
Mion, G.
ketamine research, 230
Mirzayanov, Vladimir
nerve agent development by Russia and, 3
Mission-oriented protective posture
barrier creams and, 531
gear for levels 1-4 (figure), 570
levels of (exhibit), 570–571
levels of protection, 569
patient thorough decontamination and, 543
soap and water decontamination and, 534
triage of chemical casualties and, 513, 514
water issues, 546
Mitochondrial permeability transition inhibitors
neuroprotectant use, 232
MITS JPMO. *See* Medical identification and treatment systems joint product management office
MK-801. *See* Dizocilpine
MMB4 dimethanesulfonate
development of, 653
stability concerns, 653
Modular general purpose tent system chemical-biological protec-

tive liner system
description and uses, 587
Montreal Protocol
medical aerosolized nerve agent antidote and, 652
MOPP. *See* Mission-oriented protective posture
Morgenstern, P.
long-term health effects of mustard, 312, 314
Morphine
description and incapacitating effects, 418
MS. *See* Mass spectrometry
MSMTESE. *See* 1-methylsulfinyl-2-[2-(methylthio)ethylsulfonyl] ethane
Multiservice Tactics, and Procedures for NBC Protection (Field Manual 3-11.4), 569
Murray, V.
2-chlorobenzylidene malononitrile research, 451–452
Mustard agent. *See also* Nitrogen mustard
accidental exposures, 263, 717–718, 723, 725
additives for, 135
alkylation of deoxyribonucleic acid and, 264–265, 312, 718
analysis of specimens, 706–708
analytical methods used to verify exposure to sulfur mustard in biomedical samples (table), 714–715
barrier skin creams for, 530, 531
biochemical mechanisms of injury, 263–265, 708
blister fluid analysis, 726
blood sample analysis, 718–726
carcinogenesis, 290, 312–314, 315–316
case history: mustard gas exposure in 14 children and teenagers from Halabja, Iraq (exhibit), 667
casualties caused by, 20, 261, 262–263, 266, 667
central nervous system effects, 276, 290, 315
chronic eye disease and, 314
chronic pulmonary disease and, 314
clinical cases of mustard exposure from Mofid Medical Center following the Halabja, Iraq, attack on March 17, 1988 (exhibit), 668–669
clinical effects, 266–276, 312, 356, 519, 656, 667, 669
compared with phosgene oxime and lewisite, 261, 291
Cushing's impressions, 88–89
day of death after exposure in World War I fatal mustard casualties (table), 266
decontamination issues, 277, 312
description (exhibit), 21
development and properties of, 15, 20, 83
diagnosis, 276–277, 692–693
disaster at Bari, 21, 53, 105, 262
Edgewood Arsenal, MD, production, 119
gas mask effectiveness and, 21
German production statistics, 48
Germany's experimental testing on human subjects in concentration camps, 105
hair sample analysis, 726
hospitalization and, 262, 277, 281, 670
hydrolysis of sulfur mustard to produce thiodiglycol, followed by oxidation reactions (figure), 708
initial clinical effects from mustard exposure (table), 266
Institute of Medicine study on the effects of mustard agent and lewisite exposure, 312–313, 314
introduction of, 18, 261
Italian-Ethiopian War use, 45–46
Japan's use of against China, 46
laboratory findings, 669
laboratory tests for, 277
long-term health effects, 291, 312–316
mechanism of action, 136, 312, 656
median lethal dose, 519
medical management, 83, 135
metabolism, 265
military use, 262–263
mortality rates, 266, 276, 277, 278
mutagenesis, 315–316
name derivation, 261–262
nerve agents compared with, 181
neuropsychiatric symptoms and, 315
neutralization of, 533
partial-thickness injury treatment, 283
pattern of injury, 3
pediatric population and, 669–670
pediatric signs of mustard exposure (table), 670
PFC David Allen Fisher's exposure to mustard agent during the Persian Gulf War, 106–107
properties, 263
published reports (1997-2006) of laboratory analysis of human blood samples following suspected exposure to sulfur mustard (table), 727
published reports (1995-2006) of laboratory analysis of human urine samples for glutathione reaction products following a suspected exposure to sulfur mustard (table), 720
published reports (1995-2006) of laboratory analysis of human urine samples for hydrolysis metabolites following suspected exposure to sulfur mustard (table), 719
putative mechanisms by which sulfur mustard causes tissue damage (figure), 264
rapidity of reaction to, 265, 514, 656
reaction pathway of glutathione (figure), 712
reactions with glutathione, 265
recovery time after exposure to, 262, 278, 519
reports published prior to 1995 showing laboratory analysis of human biomedical samples following suspected exposure to sulfur mustard (table), 709
reproductive toxicity, 315–316
respirator effectiveness, 25–26, 83
sample preparation methods for the gas chromatographic-mass spectrometric analysis of sulfur mustard adducts to blood biomolecules (exhibit), 724–725
sample preparation methods for the gas chromatographic/mass spectrometric/mass spectrometric analysis of the sulfur mustard urinary β-lyase metabolites (exhibit), 713
sample preparation procedure for sulfur mustard adducts to deoxyribonucleic acid in blood (exhibit), 722
scarring of epithelial surfaces and, 315
skin effects, 267–274
skin sample analysis, 726
soap and water decontamination, 533, 534
synthesis of, 116–117, 312
teratogenesis, 315–316
tissue sample analysis, 726
toxicity, 667
treatment of exposure to, 277–291, 670–672
triage issues, 519
urine sample analysis, 708–718
US production of, 117
US troop training and, 53
Veterans Administration study on the effects of mustard agent and lewisite exposure, 312–313
Vietnam War and, 57
volatility of, 135
weather considerations, 135–136, 263, 266
World War I use, 2–3, 15, 18, 20–21, 25–26, 27, 260, 261
wound decontamination and, 538
Yemen Civil War and, 57, 58
Mutagenic effects
2-chlorobenzylidene malononitrile, 448

Myasthenia gravis
treatment of, 156, 198

N

N-acetylcysteine
phosgene inhalation treatment, 354
N-methyl-D-aspartate receptor antagonists
dexanabinol, 229–230
dizocilpine, 228
gacyclidine, 230
ketamine, 230–232
memantine, 228–229
Nagao, M.
sarin research, 699
Nakajima, T.
sarin research, 695, 696
Naloxone
opioid overdose treatment, 418
Namba, T.
organophosphate insecticide exposure research, 320
NAPP. *See* Nerve agent pyridostigmine pretreatment
Nasal effects
nerve agent exposure, 172–173
Nasser, Pres. Gamal Abdul (Egypt)
Yemen Civil War and, 57–58
National Academy of Sciences
anticholinergic deliriant research and, 424
causal relationship between lewisite exposure and chronic respiratory disease, 294
National Bio-Defense Analysis and Countermeasure Center
description and role, 767
National Center for Disaster Preparedness
Mark I kit recommendations, 663
Program for Pediatric Preparedness, 683
National Defence Research Institute of Sweden
hair specimen analysis for mustard agent, 726
National Defense Authorization Act
"Defense against Weapons of Mass Destruction," 128, 754
National Defense Strategy of the United States of America, 758
National Disaster Medical System
description, 765
National Fire Protection Agency
levels of protection, 580
National Guard
domestic preparedness role, 763
National Incident Management System
command and management component, 756
description, 492, 755–756
incident-specific resources, 756
organizational outline for incident management command and coordinating centers (figure), 759
National Institute for Occupational Safety and Health
levels of protection, 580
permissible chlorine exposure level, 359
phosgene limits, 734
powered-air purifying respirators and, 544
2-chlorobenzylidene malononitrile exposure guidelines, 447, 450
Working in Hot Environments, 541
National Institute of Justice
Guide for the Selection of Chemical Agent and Toxic Industrial Material Detection Equipment for Emergency First Responders, 581
National Institute of Standards and Technology
3-quinuclidinyl benzilate monitoring, 739
National Institutes of Health
carcinogen bioassays on chemical agents, 134
1-chloroacetophenone research, 461
Project BioShield and, 251
National Medical Chemical and Biological Advisory Team
description and role, 764
National Research Council
acute exposure guidance levels for chemical agents, 143
dibenz*[b,f]*-1,4-oxazepine and, 467
1-chloroacetophenone and, 463
2-chlorobenzylidene malononitrile gene mutation and, 448
National Response Framework
coordination guidelines for DHHS, 761
description and role, 758
National Response Plan
description, 492, 755–756
federal department or agency support to state and local governments, 758–759
integration of the federal government's domestic prevention, preparedness, response, and recovery plans, 756
National Security Strategy of the United States of America, 758
National Strategy for Homeland Security, 755, 758
National Toxicology Program
2-chlorobenzylidene malononitrile carcinogenicity and, 449
NATO Handbook on the Medical Aspects of NBC Defensive Operations
mustard agent treatment, 670
NDMS. *See* National Disaster Medical System
Neostigmine
description, 158
tetrodotoxin treatment, 628
Nernst, Walther Hermann
accomplishments, 15
dianisidine chlorosulphonate development, 13–14, 15, 79, 80
Nernst Ni-Shrapnel. *See* Dianisidine chlorosulphonate
Nerve agent pyridostigmine pretreatment
description, 158
dosage considerations, 202
Nerve agents. *See also* Incapacitating agents; Neuroprotection as a treatment for nerve agent survivors; Organophosphorus compounds; Pyridostigmine bromide; Treatment of nerve agent exposure; *specific agents and types of agents*
accessibility of and ease of manufacturing, 244, 251
adducts to biomolecules, 698–701
advantages of as a weapon, 126
agents included, 661
aging half-time of nerve agents (table), 198
analytical methods for assay of nerve agent hydrolysis products (table), 697
Arab-Israeli Six-Day War and, 58
behavioral effects, 175–179
bioscavengers, 232, 244–253
cardiovascular system effects, 179–180
case history: nerve agent exposure in Nazhmar, Iran (exhibit), 662
case report: accidental exposure of a man to liquid soman (exhibit), 162–163
central nervous system effects, 175–179
chemical, physical, and environmental properties (table), 167
chemical structure (figure), 694
cholinesterase analysis, 701–706
clinical presentation, 662
compared with chlorine, phosgene, and mustard agent, 181
compared with commonly used ChE inhibitors, 166–168
compared with insecticides, 316–317
conventional wounds contaminated with, 522–523
definitions of C*t*, LCt_{50}, and LD_{50} (exhibit), 168
dermal exposure to liquid, 169–170, 185–186, 244
description, 204, 316
diagnostics, 693–706
effects of dermal exposure to liquid nerve agents (table), 169

effects of exposure to nerve agent vapor (table), 169
effects of nerve agents in humans (table), 170
effects on organs and organ systems, 170–180
exposure routes, 168–170
eye effects, 170–172
fluoride regeneration and, 699
general clinical tests, 694
general treatment principles, 180–190, 205, 316
German production of, 48
Germany's development of, 46–47
Germany's experimental testing on human subjects in concentration camps, 105
historical background of the use of, 156–158
hydrolysis compound assay, 695–698
inhalational exposure to vapor, 168–169, 185, 244
intermediate syndrome and, 318–319
laboratory findings, 662
lessons learned from Iran, Japan, and Iraq, 195–197, 223
lethality of, 244, 661
long-term health effects, 316–322
mechanism of action, 156, 159, 204–205, 662
median lethal dose, 244
methods used to confirm human exposures to nerve agent adducts to biomolecules (table), 701
methods used to confirm human exposures to nerve agents via assay of hydrolysis products (table), 698
mnemonic for cholinergic crisis (exhibit), 662
molecular models (figure), 166
muscle necrosis and, 318
nasal effects, 172–173
nerve agent antidote kits and pretreatments, 64
neuropsychiatric symptoms and, 320–321
parent compound assay, 694–695
pediatric population effects, 661–667
pediatric treatment, 195
persistent nature of, 244
pharmacology of, 166–168
physical properties, 167–168
polyneuropathy, 317
production during the 1950s, 55
pulmonary system effects, 173–174
return to duty considerations, 194–195
rocket program, 121–122
secondary contact and, 244
signs and symptoms of mild to severe exposure, 191–194
skeletal muscle effects, 174–175, 188
skin effects, 169–170, 185–186, 244, 529, 661
specific treatment by exposure category, 190–194
toxicity of, 661
toxicological studies, 322
triage considerations, 518, 520–521, 522–523
use in combination with other weapons, 244
volatility of, 134–135, 168
World War II use, 3, 48
wound decontamination and, 538
Yemen Civil War and, 57
Neuroleptics. *See* Antipsychotic drugs
Neuropathology of nerve-agent-induced brain damage
seizure-related brain damage, 224–225
seizures and status epilepticus, 223–224, 664
Neuropeptides and neuromodulators. *See also specific agents*
incapacitating effects, 420–422
Neuroprotectants
classes of drugs, 226–227
gangliosides, 227
N-methyl-D-aspartate receptor antagonists, 228–232
poly(ADP-ribose) polymerase inhibitors, 227
ryanodine receptor antagonists, 227–228
Neuroprotection as a treatment for nerve agent survivors
free radical scavengers, 232
mitochondrial permeability transition inhibitors, 232
neuropathology and the mechanism of nerve-agent-induced damage, 223–225
neuroprotectants, 226–232
"neuroprotection" definitions, 225–226
neuroprotective hypothermia, 232
relevance of neuroprotection to nerve agent survivors, 225–226
Neuroprotective hypothermia
nerve agent exposure treatment, 232
Neuropsychiatric symptoms
mustard agent exposure and, 315
nerve agent exposure and, 320–321
organophosphate insecticide exposure and, 319–320
Neurotoxic shellfish poisoning
brevetoxin and, 631
treatment, 631
Neuve-Chapelle, Battle of
dianisidine chlorosulphonate use, 14
Newmark, J.
treatment guidelines for children, 195
Ni-shells. *See* Dianisidine chlorosulphonate
Nicoloau, K.
brevetoxin research, 628
Nicotera, P.
mustard agent research, 265
Niebauer, M.
dantrolene research, 228
Niemann,
sulfur mustard synthesis, 260
NIMS. *See* National Incident Management System
1920s
airplane use for chemical attacks, 26, 118–119
Berber war with France and Spain, 42–43
Chemical Warfare Service and, 43–44
improvements in chemical weapon delivery systems, 118
new US policy on chemical warfare, 44–45
1930s
Italian-Ethiopian War, 45–46
Japanese invasion of China, 46
new chemical agent development, 119
new chemical weapon development, 119–120
organophosphorus compound development, 46–47
1940s
chemical weapon delivery system improvements, 120
1950s
Chemical Corps changes, 54–55
chemical weapon delivery system improvements, 120
incapacitant program, 55–56
Korean War, 54
medical research on human volunteers, 55
nerve agent production and development, 55
Soviet threat, 56
1960s
Arab-Israeli Six-Day War, 58
Army reorganization, 56–57
chemical warfare program changes, 59–60
chemical weapon delivery system improvements, 120–122
Dugway Proving Ground incident, 59
incapacitating chemical agent development, 59
Operation CHASE, 59, 60
psychedelic agent experiments, 3
public hostility toward chemical weapons, 59
sarin accident in Okinawa, 59
Vietnam War, 57

Yemen Civil War, 57–58
1970s
binary weapon development, 122–124
plans to abolish the Chemical Corps, 60–61
restoring the Chemical Corps, 61
restrictions on sea dumping of chemical weapons, 60
Soviet Union's use of chemical warfare agents, 61–62
Yom Kippur War, 61
1980s
Afghanistan War, 62
chemical training, 63
Haig Report, 62
Iran-Iraq War, 62–63
Soviet-US Memorandum of Understanding, 63
1990s
chemical attacks, 125
chemical weapon development in Libya, 65
Persian Gulf War, 63–65
Nishioka, N.S.
mustard agent injury treatment, 285
Nitrites
cyanide poisoning treatment, 383–384, 386, 390, 394–395, 397
Nitrogen
toxic effects of exposure, 326–327
Nitrogen dioxide
pathophysiological effects, 350
Nitrogen mustard. *See also* Mustard agent
biochemical mechanisms of injury, 263–265
description, 119
gastrointestinal tract effects, 276
potential terrorist use and, 667
synthesis of, 260
three forms of, 262
use of in chemotherapy, 260–261
Nixon, Pres. Richard M.
ban on biological warfare agents, 138
destruction of chemical weapons and, 61, 122
United States ratification of the Geneva Protocol and, 60, 137
Nonivamide. *See* Pelargonyl vanillylamide
Nonlethal weapons. *See* Incapacitating agents
Nonsteroidal antiinflammatory drugs
treatment of mustard agent exposure, 282
Noort, D.
phosgene research, 737
sarin research, 696
North Korea
chemical weapons capability, 145
Notes on Gas as a Weapon in Modern War, 90
Nozaki, H.
patient thorough decontamination research, 540
NRF. *See* National Response Framework
NRP. *See* National Response Plan
NSAIDs. *See* Nonsteroidal antiinflammatory drugs
NSP. *See* Neurotoxic shellfish poisoning
Nunn, Sen. Sam
chemical warfare comments, 125
Nunn-Lugar Cooperative Threat Reduction Program
Russia's elimination of chemical weapons and, 144
Nunn-Lugar-Domenici Act
domestic preparedness program provision, 128, 754–755

O

O-chlorobenzylidene malononitrile
acute effects, 447–448
acute inhalation toxicity of CS in animals (table), 448
animal studies of effects, 448–449
carcinogenicity studies, 449
characteristics of (table), 445
chemical structure (figure), 446
chronic toxicology, 449
clinical effects, 447–452
deployment of, 444
exposure guidelines, 447
human studies, 449–452
incapacitating effects, 416, 444
inhalation toxicology studies, 448
introduction of, 342, 443
long-term effects, 452
personal defense spray use, 443
physical characteristics, 444
repeat exposures, 448–449
safety of, 472
severe medical complications, 452
subclinical toxicology studies, 449
symptoms of exposure to, 444
thermal degradation products, 444, 446–447
Vietnam War use, 444
O-ethyl N,N-dimethyl phosphoramidocyanidate. *See* Tabun
O-ethyl-S-[2(diisopropylamino)ethyl]. *See* VX nerve agent
OC. *See* Oleoresin capsicum
Occupational health and the chemical surety mission
administrative documentation to support a chemical surety inspection (exhibit), 606–607
advising agencies for the treatment of chemical agent injury (exhibit), 595
categorization of workers based on their likelihood of exposure to chemical agents (exhibit), 601
chemical agent definition, 594
chemical agent workplace, 596–597
Chemical Surety (AR 50-6), 594
chemical surety definition, 594
demilitarization of chemical warfare agents, 609–611
information sources for chemical surety, 594
inspection of chemical storage containers, 596
installation medical authority responsibilities, 594, 599–604, 608
medical aspects of a chemical accident or incident response and assistance, 607–609
Medical Management of Chemical and Biological Casualties Course, 594–595, 608
medical response team and, 607–609
medical support of the chemical personnel reliability program, 599, 605–607
medical surveillance for chemical agent workers, 597–604
personal protective equipment needs, 596–597, 599
refresher training programs, 605
safe treatment and disposal of chemical agents and weapons, 596–597
Toxic Chemical Training Course for Medical Personnel, 594–595, 608
training and education for chemical agent workers, 604–605
understanding patients' occupational healthcare needs and, 595
Occupational Health Guidelines for the Evaluation and Control of Occupational Exposure to Mustard Agents H, HD, and HT
chemical surety resource, 594
potential exposure evaluations, 602
RBC-ChE monitoring, 601
Occupational Health Guidelines for the Evaluation and Control of Occupational Exposure to Nerve Agents GA, GB, GD, and VX
categories of personnel required to have RBC-ChE measured, 601
chemical surety resource, 594
potential exposure evaluations, 602

Occupational Safety and Health Administration
disaster and medical response to mass casualty events, 492
fixed decontamination shelter recommendations, 545–546
hazardous waste operations and emergency response training, 515
levels of personal protective equipment (exhibit), 542, 580
monitoring of decontamination personnel guidelines, 542
OSHA Best Practices for Hospital-Based First Receivers of Victims from Mass Casualty Incidents Involving the Release of Hazardous Substances, 493
permissible chlorine exposure level, 359
personal protective equipment guidelines, 515
powered-air purifying respirators and, 544
work-rest cycle recommendations, 495–496
Ochsner, Gen. Hermann
nonlethal gas attacks on Soviet troops, 52
views on chemical warfare, 49
Office of the Surgeon General
CBRNE programs and, 768
Oise-Aisne offensive
chemical attacks, 32
US participation (figure), 33
Okinawa
accidental release of sarin, 59, 60
Oklahoma City
bombing of the Murrah Federal Building, 754
Okumura, T.
Aum Shinrikyo sarin attack on the Tokyo subway, 493
patient thorough decontamination research, 540
Olajos, E.J.
oleoresin capsicum research, 455
tear gas research, 342
Oleoresin capsicum
acute effects, 454
characteristics of (table), 445
chemical structure (figure), 453
clinical effects, 454–455
deployment methods, 453
description, 452–453
FBI research on, 443
historic use of, 453
long-term effects, 455
medical complications, 455
medicinal use of, 453
personal protection use, 443
physical characteristics, 453
physiological effects, 453, 454
safety of, 472
US Postal Service use, 442
1-chloroacetophenone
animal studies, 460–461
carcinogenicity, 461
characteristics of PS, CN, DM, and CR (table), 458–459
chemical structure (figure), 460
deployment methods, 460
description, 457
harrassing dose, 461
human studies, 461–464
incapacitating effects, 416
invention of, 442
long-term effects, 463–464
personal defense spray use, 443
physical characteristics, 457, 460
physiological effects, 460
severe medical complications, 464
sublethal effects, 461
toxicology, 460–461
volunteer acute exposure studies, 461
"120 Cities Program"
description and focus of, 755
1-methylsulfinyl-2-[2-(methylthio)ethylsulfonyl]ethane
urine sample analysis for mustard agent and, 711, 716–717
1,1′-sulfonylbis[2-(methylsulfinyl)ethane]
urine sample analysis for mustard agent and, 711, 717, 718
OPCW. *See* Organization for the Prohibition of Chemical Weapons
Operation CHASE
chemical weapon dumping and, 59, 60
Operation Desert Shield, 64
Operation Desert Storm. *See also* Persian Gulf War
accidental battlefield exposure to chemical agents, 129–130
description, 64–65
pyridostigmine bromide therapy and, 202–204
Operation Enduring Freedom
September 11, 2001, attacks and, 65
Operation Iraqi Freedom
improvised explosive devices and, 130
Iraq's failure to report its chemical warfare research and weapons production and, 65–66
Operation Solid Shield, 87
field training for chemical attacks, 106
OPIDN. *See* Organophosphorus ester-induced delayed neurotoxicity
Opioids. *See also specific agents*
cyanide poisoning treatment, 523
description and incapacitating effects of, 418–419, 421
nerve agent exposure treatment, 523
overdose treatment, 418
pediatric population and, 667
popularity as illicit drugs, 419
side effects, 667
OPs. *See* Organophosphorus compounds
Oral effects
2-chlorobenzylidene malononitrile, 448
Organization for the Prohibition of Chemical Weapons
Chemical Weapons Convention and, 138, 140–141
Organophosphate insecticides. *See also specific agents*
compared with nerve agents, 316–317
electroencephalographic effects, 321
intermediate syndrome and, 318
muscle necrosis and, 317–318
neuropsychiatric symptoms and, 319–320
polyneuropathy, 317
Organophosphorus compounds. *See also* Insecticides; Nerve agents; *specific agents*
anticholinesterase use, 251–252
atropine treatment, 184
brain injury and, 223
cardiac arrhythmias and, 190
categorization of (exhibit), 47
compounds included, 158
earliest reported incident of toxicity from, 47
German development of, 46–47
incapacitating effects, 416
mechanism of action, 161, 244, 701
original use for, 244
pediatric effects, 658, 661
physostigmine development, 46
Test-Mate OP Kit field-forward assay, 693
tetraethyl pyrophosphate development, 46–47
toxicity of, 661–662, 701
Organophosphorus ester-induced delayed neurotoxicity
description, 317
Orrenius, S.
mustard agent research, 265

OSHA Best Practices for Hospital-Based First Receivers of Victims from Mass Casualty Incidents Involving the Release of Hazardous Substances, 493
Osmond, Humphry
"psychedelic" definition and, 416
OTZ. *See* 2-oxothiazolidine-4-carboxylic acid
Owens, E.J.
dibenz*[b,f]*-1,4-oxazepine research, 468
Oxides of nitrogen
air pollution and, 344–345
diagnosis of exposure to, 358
forms of, 344
sources of, 358
toxic effects of, 326–327, 358
Oximes. *See also* Mark I kits; *specific agents*
administration considerations, 188–189, 702
antidote treatment nerve agent autoinjector and, 188, 189
combined with atropine, 183, 188, 223
cyclosarin exposure and, 202
description, 186
differences among agents, 187
dosage considerations, 187–188
mechanism of action, 186–187
nerve agent exposure treatment, 186–189, 197–198, 663, 702
pediatric population and, 663

P

P-aminopropiophenone
cyanide poisoning treatment, 394, 396
Palestine
Israel's possible use of DM against, 443
Palmer, Col. John M.
military training program comments, 56
Palytoxin
accidental exposure, 620
adverse effects of human palytoxin intoxication (exhibit), 621
bioterrorism threat from, 622
chemical structure (figure), 618
clinical signs and symptoms of intoxication, 619
health effects, 619
laboratory findings, 619–620
lethality of, 622
mechanism of action, 617–618
median lethal dose, 618–619
physical examination results, 619
primary source, 617
protection against, 622
public health surveillance programs, 622
routes of exposure, 619, 620, 622
sodium channel effects, 617–618
stability of, 622
synthesis, 617
toxicity, 618–619, 620
treatment, 620–622
Papaverine
palytoxin intoxication treatment, 622
Papirmeister, B.
mustard agent research, 278
PAPP. *See* P-aminopropiophenone
Paralytic shellfish poisoning
clinical signs and symptoms, 625–626
food sources, 624–625
physical examination and, 626
red tide blooms and, 622
saxitoxin and, 622, 624–625, 625–626
tetrodotoxin and, 624–625
Parathion
blood cholinesterase inhibition and, 165
eye effects of exposure to, 170
insecticide use, 158
muscle necrosis and, 318
Paris Convention. *See* Chemical Weapons Convention
PARP inhibitors. *See* Poly(ADP-ribose) polymerase inhibitors
Patel, Marilyn Hall
gas chamber executions with cyanide and, 374
Patient protective wraps
description and uses, 587
Patient thorough decontamination
benefits of, 540
civilian sector and, 540–541
decontamination shelters, 544–546, 552
decontamination worker protection, 541–543
description, 500, 528
detection devices, 544
handling patients, 547
hospital areas for, 529
individual protective equipment, 543–544
medical monitoring, 541
musculoskeletal injury to decontamination workers, 541
need for, 539–540
night operations and, 547–548
personnel needs, 540–541
transport equipment, 544
water concerns, 546–547
work-rest cycles for workers, 542, 543
worker safety and, 541–543
wound contamination and, 538
PATS. *See* M41 protection assessment test system
Pattle, R.E.
dibenz*[b,f]*-1,4-oxazepine research, 467
Paulet, G.
cyanide poisoning research, 394, 396
PAVA. *See* Pelargonyl vanillylamide
PB. *See* Pyridostigmine bromide
PbTx. *See* Brevetoxin
PCP
description and incapacitating effects, 419
treatment for intoxication by, 420
Pediatrics. *See* Infants and children; Medical management of chemical toxicity in pediatrics
Pelargonyl vanillylamide
chemical structure (figure), 453
police department use, 443
synthesis of, 453
Pentazocine
description and incapacitating effects, 418–419
Pereira, M.A.
phosgene research, 737
Perfluoroisobutylene
nonmilitary uses, 357
physiological effects, 354
supportive care for exposure to, 358
toxic effects of, 324, 326, 345
toxic fumes from, 357–358
treatment for inhalation of, 354
Periodic medical examinations for chemical workers
comparing data from preplacement examinations, 600
frequency and extent of, 600–601
interval medical history and physical, 601
Pershing, Gen. John J.
AEF leadership, 22, 24, 25, 27, 33, 36, 89
comments on the importance of chemical warfare, 41
Pershing missiles
nerve agent delivery, 122

Persian Gulf War. *See also* Operation Desert Storm
chemical weapons and, 63–65, 106–107
"Gulf War" syndrome, 64
nerve agent antidote kits and pretreatments, 64, 704
PFC David Allen Fisher's exposure to mustard agent, 106–107
pyridostigmine bromide therapy and, 202–204
use of 3-quinuclidinyl benzilate by Iraq, 413
Pert, Candace
morphine research, 418
Pesticides. *See* Organophosphate insecticides
Petras, J.M.
nerve-agent-induced brain damage research, 223
PFIB. *See* Perfluoroisobutylene
Pharmacology of cholinesterase inhibitors
blood cholinesterases, 161–166
cholinesterase in tissue, 158
cholinesterase-inhibiting compounds, 158–159
inhibition of blood cholinesterases, 164–166
mechanism of action, 159–161
nerve agents, 166–168
Phenethylamine-based psychedelics
description and effects of, 418
Phenothiazines
LSD intoxication treatment, 417
Philippe, Henri
Champagne-Marne Defensive and, 30
Phosgene
accidental release of, 134
animal studies, 735
chemical reactivity, 354
combined with chlorine or diphosgene, 341
compared with phosgene oxime, 294
cysteine adducts, 736
development of, 15, 734
earliest reported description involving chemical warfare on the AEF (exhibit), 22
Edgewood Arsenal, MD, production, 119
France's weaponizing of, 341
Germany's experimental testing on human subjects in concentration camps, 105
glutathione and glutathione adducts and, 735–736
inflammatory pathways, 350–351
inhalation of, 734–735
interleukin-6 levels and, 737–738
latent period for symptoms, 324–325
lethal dose, 735
long-term health effects of exposure, 324–326, 354
macromolecule adducts, 737
mechanism of action, 136, 734
metabolism and markers for exposure, 735–737
nerve agents compared with, 181
nonmilitary uses, 345
odor of, 734, 735
pathophysiological effects, 348, 349, 734
pediatric effects of exposure to, 673
physiological responses, 348, 354, 734
properties and attributes of (exhibit), 19
regulatory threshold limit value, 734
replacement of chlorine with, 18
small molecule adducts, 736–737
synthesis of, 116
toxicity of, 734
treatment for inhalation of, 354–355, 363
triage issues, 521, 522
US production of, 117
vapor pressure, 734
"white star" mixture with chlorine, 19–20
World War I use, 2, 19–20, 25–26, 83, 341
Yemen Civil War and, 57
Phosgene oxime
biochemical mechanisms of injury, 294
clinical effects, 295
compared with mustard agent and lewisite, 261
compared with phosgene, 294
eye effects of exposure, 295
military use, 294
patient management, 295
properties, 294
pulmonary effects of exposure, 295
putative mechanisms by which phosgene oxime causes tissue damage (figure), 294
skin effects of exposure, 295
pHuBChE. *See* Plasma-derived human butyrylcholinesterase
Physostigmine
adverse effects, 426, 704
chemical structure (figure), 198
compared with huperzine A, 704
deliriant intoxication treatment, 425–426, 523
description, 158
development and isolation of, 46
mechanism of action, 425, 426
PCP intoxication treatment, 420
3-quinuclidinyl benzilate intoxication treatment, 426
Pinacoloxymethyl-fluorophosphonate. *See* Soman
Plasma-derived human butyrylcholinesterase
administration of, 247
advantages for human use, 246–247, 252, 253
availability of, 249, 653
behavioral safety of, 248–249
Cohn Fraction IV-4 paste source, 247, 249, 251
compared with fetal bovine serum AChE, 245
efficacy of, 247–248, 252
immunological safety of, 248, 252
pharmacokinetics, 247, 252–253, 702
prophylactic dose, 247
protection by human butyrylcholinesterase against nerve agent poisoning (table), 252
purification from human plasma, 247
pyridostigmine bromide and, 251
recombinant type, 249–250
safety of, 247, 252–253
sarin and, 698–699
stability of, 247, 252
Plasma-derived stoichiometric bioscavengers
cholinesterases, 245–247
compared with catalytic bioscavengers, 250
plasma-derived human butyrylcholinesterase, 245–247
Playfair, Lyon
cacodyl cyanide artillery shell proposal, 11
Point detectors
chemical agent detector kits, 576–577
improved chemical agent detectors, 576
M22 automatic chemical agent detector and alarm, 577
M8 chemical agent detection paper, 575
M9 chemical agent detection paper, 575–576
M272 chemical agent water testing kits, 577
Polhuijs, M.
sarin research, 696, 698–699
Poly(ADP-ribose) polymerase inhibitors
soman-induced seizure-related brain damage treatment, 227
Polymer fume fever
perfluoroisobutylene and, 358
polytetrafluoroethylene and, 345
Polyneuropathy

nerve agents and, 317
organophosphate insecticides and, 317
Polytetrafluoroethylene
formation of toxic gases, 345
pathophysiological effects, 349–350
polymer fume fever and, 345
Porcine heterograft
mustard agent injury dressing, 280
Porter, E.
2-chlorobenzylidene malononitrile research, 446
Porter, Maj. Gen. William N.
chemical weapon warnings, 48
Posttraumatic stress disorder
comorbidity with other mental illness, 321
nerve agent exposure and, 175, 319, 321
pediatric population and, 660, 680
Powered dermabrasion
mustard agent injuries and, 284
Powers, Francis Gary
saxitoxin capsules and, 628
Pregnant women
cyanide poisoning treatment, 385
pyridostigmine bromide pretreatment safety, 201
sarin exposure and treatment, 196
Preplacement examinations for chemical workers
baseline data, 600
factors restricting the wearing of protective clothing and, 600
functions of, 600
heat stress monitoring and, 603–604
job description and, 599
medical history questionnaire, 600
Pretreatment therapy for nerve agent poisoning
huperzine A, 704–706
pyridostigmine bromide, 158, 197–204, 244, 252, 651, 704
Professional officer filler information system
area medical laboratories' endemic diseases section and, 764
MEDCOM personnel and, 764
PROFIS. *See* Professional officer filler information system
Program for Pediatric Preparedness
goals of, 683
Web site, 683
Project 80
description, 56
Project 112
description, 56
Project BioShield
interagency partnership on, 251
Projectors
attacks on the AEF (exhibit), 26
binary weapons and, 123
CWS standardization of, 120, 121–122
description, 26
Livens projectors, 118, 119
rockets, 120, 121–122
VX nerve agent delivery, 121–122
Protective clothing
boots, 573
fabrics for, 569
factors in the decision to wear, 569
gloves, 573–574
heat and, 569
joint service lightweight integrated suit technology, 572–573
MOPP levels and, 569
protective ensembles, 572–573
Protective equipment. *See* Gas masks; Respirators; Individual protective equipment
PS. *See* Chloropicrin
PSP. *See* Paralytic shellfish poisoning
Psychedelic agents. *See* Indole-based psychedelics
Psychochemicals. *See* Incapacitating agents
Psychological effects
chemical weapons, 2, 19–20
cyanide poisoning, 393–394
pediatric population and, 660
PTSD. *See* Posttraumatic stress disorder
PTX. *See* Palytoxin
Pulmonary system. *See also* Inhalational exposure to nerve agent vapor; Inhalational injury from toxic industrial chemicals; *specific agents and disorders*
batrachotoxin effects, 633
brevetoxin effects, 630
chlorine effects, 673
chloropicrin effects, 456–457
chronic pulmonary disease, 314
dibenz*[b,f]*-1,4-oxazepine effects, 467–468
diphenylaminearsine effects, 466
incapacitating agent effects, 442, 471–472
intubation, 288
lewisite exposure effects, 293, 294
mustard agent exposure and, 275, 287, 288–290, 290–291, 312, 313–314, 670, 672
nerve agent exposure effects, 173–174
oleoresin capsicum effects, 454
1-chloroacetophenone effects, 461–462
onset of symptoms, 275
paralytic shellfish poisoning effects, 626
pediatric exposure to toxic agents and, 659
phosgene exposure effects, 295, 325–326
pulmonary cancer relationship to mustard agent exposure, 313–314
respiratory failure, 174
2-chlorobenzylidene malononitrile effects, 447–449, 449–450
ventilation considerations, 173
Pulsed CO2 laser ablation
mustard agent injury treatment, 284
Pumiliotoxin
sodium channel effects, 617
Punte, C.L.
1-chloroacetophenone research, 461
2-chlorobenzylidene malononitrile research, 449, 450, 451
Pyridostigmine
chemical structure (figure), 198
myasthenia gravis treatment, 156, 198
nerve agent exposure treatment, 174, 244
soman exposure and, 179
Pyridostigmine bromide
adverse effects, 201, 202–203
compared with atropine and oxime therapy, 199–200
dosage considerations, 202, 704
effect of therapy on median lethal dose in monkeys exposed to soman (table), 199
effect of therapy with and without pyridostigmine pretreatment on protective ratios in animals exposed to nerve agents (table), 200
effects of pyridostigmine pretreatment on US soldiers in the Persian Gulf War (table), 203
efficacy of for pretreatment, 158, 199–201, 202, 704
FDA post-marketing studies, 652
informed consent issues, 204, 650–651
interaction with other commonly used battlefield medications, 201–202
myasthenia gravis treatment, 158
"off-label" use of, 650
pretreatment for nerve agent poisoning, 197–204, 244, 252, 651,

704
red blood cell and acetylcholinesterase protection studies using pyridostigmine bromide and huperzine A after ex-vivo exposure to soman (table), 705
regulatory status, 204
safety of administration, 201–202
surgery and, 204
unexplained medical symptoms and, 203–204
wartime use, 202–204

Q

Quayle, Vice Pres. Dan
chemical weapon comments, 64
Queen, F.B.
1-chloroacetophenone research, 463

R

RADS. *See* Reactive airways dysfunction
Rapsahl, Julius
warning of a German gas attack, 80
Raveh, L.
fetal bovine serum AChE research, 245
plasma-derived human butyrylcholinesterase research, 245–246, 249
RBC-ChE. *See* Red blood cell cholinesterase
Reactive airways disease syndrome
2-chlorobenzylidene malononitrile exposure and, 452
Reactive airways dysfunction
sulfur dioxide and, 345
2-chlorobenzylidene malononitrile and, 342
Reactive Skin Decontamination Lotion
description, 533, 536–537, 652–653, 653
development of, 652–653
M291 SDK and, 536, 653
safety of, 653
Read, R.W.
urine sample analysis for mustard agent, 711, 716, 717
Reagan, Pres. Ronald
binary chemical weapons and, 3, 124–125
Recombinant human butyrylcholinesterase
clinical trials, 653–654
sources of, 249–250
Recombinant stoichiometric bioscavengers
recombinant human butyrylcholinesterase, 249–250
Red blood cell cholinesterase
description, 158
monitoring, 161, 163
periodic medical examinations for chemical workers and, 600
preplacement examinations for chemical workers and, 600
temperature effect on inhibition, 165
Regional Emergency Medical Advisory Committee of New York City
pediatric nerve agent antidote dosing schedule, 684
Remifentanyl
description and use of, 667
Rengstorff, R.H.
dibenz*[b,f]*-1,4-oxazepine research, 468
1-chloroacetophenone research, 463
2-chlorobenzylidene malononitrile research, 450–451
Renshaw, B.
long-term health effects of mustard agent, 315
Republican National Convention of 2004
CDC Enhanced Surveillance Program data, 622
Respirators. *See also* Gas masks
clearances for chemical workers, 602
effectiveness against mustard agent, 25–26, 83
fit issues, 560, 563
powered-air purifying type, 544
training in use of, 560
use of for children, 657
Respiratory protection
general principles, 561
joint service general purpose masks, 567–568
joint service mask leakage tester, 563, 564–565
M45 chemical-biological masks, 566–567
M53 chemical-biological protective masks, 568–569
M41 protection assessment test system, 563, 564
M42A2 chemical-biological combat vehicle masks, 566
M40A1 chemical-biological field masks, 565–566
masks, 561–569
MCU-2/P chemical-biological masks, 566
small box respirators, 561
Return to duty
mustard agent exposure and, 290–291
nerve agent exposure and, 194–195
Rhoads, Dr. Cornelius P.
Bari disaster and, 105
Rhodanese
hydrogen cyanide inhalation treatment, 353–354
rHu BChE. *See* Recombinant human butyrylcholinesterase
Rice, P.
mustard agent injury treatment, 285
Riche, Alfred
synthesis of mustard agent, 117, 260
Ricin
CDC categorization as a category B threat agent, 616
Rinkel, Max
lysergic acid diethylamide research, 413
Riot control agents. *See* Incapacitating agents
Ritter, Franz
sarin research, 47
Rivastigmine
Alzheimer's disease treatment, 158
Rockets
"Honest John" rocket, 122
"Little John" rocket, 122
nerve agent delivery, 120, 121–122, 157
Roman empire
ancient use of toxic smoke, 10–11, 78
cyanide use, 372–373
incapacitating agent use, 443
Roosevelt, Pres. Franklin D.
no-first-use policy for chemical weapons, 52, 137
Rosenstock, L.
organophosphate insecticide exposure research, 320
Rotenberg, J.S.
cyanide poisoning research, 674
treatment guidelines for children, 195
Roth, V.S.
2-chlorobenzylidene malononitrile research, 452
Rowntree, D.W.
organophosphate insecticide exposure research, 320
Royal Army Medical Corps
advanced dressing stations, 87
base hospitals, 87
casualty clearing stations, 87
collecting, evacuating, and distribution zones, 85
Dr. Harvey Cushing's account of Royal Army Medical Corps capabilities, Flanders, Belgium, May 5, 1917 (exhibit), 88
evacuation modes, 87
main dressing stations, 87
regimental aid posts, 86–87
responsibilities, 85

Royall, Under Secretary of War Kenneth C.
chemical warfare comments, 53
RSDL. *See* Reactive Skin Decontamination Lotion
Rüdiger, Col.,
sarin research, 47, 156
Russia
Chemical Weapons Convention and, 3, 65, 157
demilitarization of chemical agents and, 144–145
stockpile destruction (table), 144
use of fentanyl in the Chechen hostage situation, 3, 65, 107, 413, 419
Russian VX. *See also* VX nerve agent
chemical structure (figure), 694
Ryanodine receptor antagonists
soman-induced seizure-related brain damage treatment, 227–228

S

Sacco triage method
description, 517
Saddam Hussein
bombing of Sardasht using mustard agent, 656
Iraq's chemical weapon capabilities and, 64
Iraq's invasion of Kuwait and, 63–64
Saint Mihiel offensive
chemical attacks, 32–33
division field hospitals, 95–96
medical support for the treatment of chemical casualties, 99
overview and detailed map of US participation (figure), 34
Salem, H.
hydrogen cyanide research, 354
incapacitating agent research, 442
oleoresin capsicum research, 455
tear gas research, 342
Salt Lake City, UT
accidental release of ammonia, 145
Sandberg, C.G.
cyanide poisoning research, 393
Sarin
accidental exposure of two US soldiers to in Baghdad, 157–158, 168, 195, 197
advantages of as a weapon, 126
animal testing of, 47
atropine treatment, 179
Aum Shinrikyo cult attack with sarin in the Tokyo subway, 4, 125, 127–128, 158, 178, 181–182, 193, 196–197, 223, 244, 316, 317, 321, 492, 518, 540, 657, 695–696, 699, 754
behavioral effects of exposure, 175, 176
carboxylesterase and, 246
case report: exposure of three men to sarin (exhibit), 172
chemical structure (figure), 694
clinical effects, 316
codenames for, 47
electroencephalographic effects of exposure, 177, 321–322
German production of, 48, 119, 156
hydrolysis pathway of sarin, soman, and cyclosarin (figure), 696
intermediate syndrome and, 318–319
Iran-Iraq War and, 157, 195–196
molecular model (figure), 166
muscle necrosis and, 318
plasma-derived human butyrylcholinesterase and, 245
polyneuropathy and, 317
production during the 1950s, 55
projectile delivery, 121–122
properties of, 3
pulmonary system effects, 173–174
signs and symptoms reported by Tokyo hospital workers treating victims of sarin subway attacks (table), 541
Soviet Union production of, 156
synthesis of, 693
toxicity and lethality of, 47, 693
toxicological studies, 322
2-pyridine aldoxime methyl chloride treatment, 187
US production of, 120
volatility of, 134, 168
Saudi Arabia. *See* Arab-Israeli Six-Day War
Saunders, Bernard Charles
diisopropyl fluorophosphate research, 48
Saxitoxin
chemical structure (figure), 623
clinical signs and symptoms of poisoning, 624–626
laboratory findings, 626–627
lethal dose, 623–624
mechanism of action, 623
monitoring, 627
protection issues, 628
sodium channel effects, 617, 623
sources of, 622
stability, 627, 628
synthesis, 622–623
toxicity, 623–624
treatment, 627, 628
SBME. *See* 1,1′-sulfonylbis[2-(methylsulfinyl)ethane]
Scheele, Carl Wilhelm
cyanide research, 116, 373
discovery of chlorine, 116
Schouosboe, A.
dantrolene research, 228
Schrader, Gerhard
organophosphorus compound research, 47
sarin research, 156
tabun research, 47, 156, 693
Schwarzkopf, Gen. H. Norman
chemical warfare comments, 64
Sciuto, A.M.
phosgene research, 348, 736, 737–738
Scopolamine
description and incapacitating effects, 421, 422
SE. *See* Status epilepticus
Seizure-related brain damage
description, 223
mechanisms contributing to nerve-agent-induced SRBD (figure), 225
neuropathology of, 224–225
secondary stroke injury and, 226
Seizures
brain damage cause, 223
central nervous system effect of nerve agent exposure, 178–179, 244
neuropathology of, 223–224
seizure-related brain damage, 223
status epilepticus and, 223
therapeutic window, 223
September 11, 2001, terrorist attacks
domestic preparedness issues, 755–758, 765, 767–768, 769
Operation Enduring Freedom and, 65
Strategic National Stockpile and, 765
Serotonin 5-HT
incapacitating effects, 421
SERPACWA. *See* Skin exposure reduction paste against chemical warfare agents
Settle, J.A.D.
mustard agent exposure treatment, 279

Shaw, F.H.
organophosphate insecticide exposure research, 319, 320
Shellfish poisoning. *See* Brevetoxin; Saxitoxin; Tetrodotoxin
Shih, T.M.
dizocilpine research, 228
memantine research, 228
Shryock, Richard
Vedder's comments on, 108
Sibert, Maj. Gen. William L.
Chemical Warfare Service leadership, 22, 90
Silver nitrate solution
treatment of mustard agent injuries, 280
Silver sulfadiazine cream
treatment of mustard agent injuries, 281, 670, 671
Silverlon
mustard agent injury dressing, 280
Simple triage and rapid treatment system
description, 517
Six-Day War. *See* Arab-Israeli Six-Day War
Skeletal muscle system
brevetoxin effects, 630
effects of nerve agent exposure, 174–175, 188, 318
effects of organophosphate insecticide exposure, 317–318
muscle necrosis and, 317–318
paralytic shellfish poisoning effects, 626
saxitoxin effects, 627
tetrodotoxin effects, 627
Skin cancer
mustard exposure and, 313
Skin effects of chemical agents. *See also specific agents*
active barrier creams, 531–532
active topical skin protectant and, 531–532
barrier skin creams and, 530–532
classes of barrier creams, 531
factors affecting the absorption of agent, 529–530
patents covering work on active topical skin protectant at the US Army Medical Research Institute of Chemical Defense (table), 532
pediatric population and, 659
skin "compartments," 529
skin exposure reduction paste against chemical warfare agents, 530–531
Skin effects of incapacitating agents
chloropicrin, 457
dibenz*[b,f]*-1,4-oxazepine, 468
diphenylaminearsine, 466
oleoresin capsicum, 454–455
1-chloroacetophenone, 461, 462–463
treatment, 471
2-chlorobenzylidene malononitrile, 448, 450–451
Skin effects of lewisite exposure
blistering, 292–293
erythema, 292
Skin effects of mustard agent exposure
bulla description, 267, 671
compared with toxic epidermal necrosis, 278, 279
cosmetic and/or functional deficits, 278
current treatments, 278–281
cutaneous sensitivity, 315
cytopathology, 269–270
erythema, 267, 268, 279, 667
healing time for skin lesions, 268, 270, 278
hyperpigmentation, 268–269, 315, 672
immediate treatment improvements, 281–282
improved therapies, 281–287
injury assessment, 282–283
models and histopathology, 270–271
onset of symptoms, 267, 312
penetration of the skin, 529
return to duty considerations, 291
scarring of epithelial surfaces, 315
skin cancer, 313, 315
skin proteins and immunohistopathology, 272–274
thermal burns compared with, 278–279, 290
threshold amount needed to produce skin lesions, 267, 312
treatments, 278–287, 290
ultrastructural pathology, 271–272
vesication, 267, 270–274, 279–281
Skin effects of toxin intoxication
brevetoxin, 630
palytoxin, 620, 621
tetrodotoxin, 627
Skin exposure reduction paste against chemical warfare agents
application of, 531
barrier properties, 530–531
components, 530, 532
development of, 530
effectiveness, 531
effects on decontamination, 531
function, 531
M291 skin decontamination kits and, 652
Skin exposure to liquid nerve agents
atropine treatment, 185–186
compared with inhalational exposure, 169–170
effects of dermal exposure to liquid nerve agents (table), 169
factors in effects of, 169
Skin substitutes
advantages of, 286
mustard agent injury treatment, 286–287
selection of, 286
Sleep-Eze
description and uses, 421
Small Business Innovative Research Program
funding for seizure detectors, 223
Smoking
cyanide levels and, 323, 324, 374, 731
endogenous cyanide concentrations for smokers and non-smokers (table), 381
SNS. *See* Strategic National Stockpile
Snyder, Solomon
morphine research, 418
Soap and water (hydrolysis)
infants and children and, 551, 677
mechanism of action, 533–534
patient thorough decontamination and, 534, 544
skin decontamination method, 533–534
water concerns, 546
Sodium channel toxins. *See also* Batrachotoxin; Brevetoxin; Pumiliotoxin; Saxitoxin; Tetrodotoxin
three-dimensional representation of a voltage-gated sodium channel sitting in a phospholipid bilayer membrane (figure), 624
Sodium nitrite
cyanide poisoning treatment, 383–384, 394–395, 675–676
hydrogen cyanide inhalation treatment, 353
limitations of, 396
side effects, 394
use in children, 390
Sodium thiosulfate
combined with hydroxocobalamin, 396, 676
cyanide poisoning treatment, 383, 386, 390, 391, 396, 397, 675–676
dosage considerations, 396
hydrogen cyanide inhalation treatment, 353

Solomon, I.
2-chlorobenzylidene malononitrile research, 452
Soman
additives for, 135
aging half-time, 316
assays for, 699
atropine treatment, 179
barrier creams and, 531
behavioral effects of exposure, 176
capture of research documents, 51
carboxylesterase and, 246
case report: accidental exposure of a man to liquid soman (exhibit), 162–163, 312
central nervous system effects, 416
chemical structure (figure), 694
diazepam treatment, 179
effect of therapy on median lethal dose in monkeys exposed to soman (table), 199
effects of soman on acetylcholinesterase activity in whole blood from human volunteers who had taken pyridostigmine bromide (figure), 706
effects of soman on acetylcholinesterase activity in whole blood from human volunteers who were given an increasing dose of huperzine A (figure), 707
fetal bovine serum AChE and, 245
hydrolysis pathway of sarin, soman, and cyclosarin (figure), 696
incapacitating effects, 416
median lethal dose, 694–695
molecular model (figure), 166
muscle necrosis and, 318
neuropsychiatric effects, 320
oxime treatment and, 189
plasma-derived human butyrylcholinesterase and, 245–249
pulmonary system effects, 174
pyridostigmine bromide pretreatment, 179, 199, 201, 704
red blood cell and acetylcholinesterase protection studies using pyridostigmine bromide and huperzine A after ex-vivo exposure to soman (table), 705
seizure-related brain damage, 224–225, 226–232, 244
severe exposure to, 161
synthesis of, 48, 157, 693
toxicity and lethality of, 47, 693
toxicological studies, 322
volatility of, 168
Somme, Battle of the
"white star" mixture of phosgene and chlorine and, 19
Sommervell, Maj. William V.
symptomology of gas poisoning, 91
Sommervillier, Battle of
phosgene and chloropicrin attacks, 25–26
Soviet Union. *See also* Russia
Afghanistan War and, 62
Biological Weapons Convention and, 61–62
capture of soman research documents, 51
chemical weapons threat, 56
"Foliant" chemical agent program, 3
Memorandum of Understanding with the United States on prohibiting chemical weapons, 63
nerve agent weaponization, 3
no-first-use policy on chemical weapons during World War II, 51–52
sarin and tabun production, 156
US-Soviet weapons destruction agreement, 138
use of chemical warfare agents in the 1970s, 61–62
Spain
Berber war, 42–43
Spanish influenza
effects of, 101
Speer, Albert
views on chemical warfare, 49–50
Spray delivery
description, 132
nerve agents, 120, 157
SRBD. *See* Seizure-related brain damage
SS *John Harvey*
mustard agent disaster at Bari, Italy and, 21, 53, 262
Stafford Act
federal department or agency support to state and local governments and, 758–759
overview of the initial federal involvement under the Stafford Act (figure), 760
Stahl, C.J.
1-chloroacetophenone research, 463
Stalin, Josef
no-first-use policy on chemical weapons during World War II, 51–52
Stander, T.
1-chloroacetophenone research, 463
Standoff detectors
early warning for line-of-sight distances, 577
joint services lightweight standoff chemical agent detectors, 579
M21 remote sensing chemical agent alarms, 578–579
Stanton, Secretary of War Edwin M.
Doughty's chemical warfare proposal and, 12
Staphylococcal enterotoxin B
CDC categorization as a category B threat agent, 616
Stark, Col. A.N.
emergency gas teams and, 97
START triage system
description, 517
Status epilepticus
brain damage cause, 223
definition of, 223
nonconvulsive type, 223
pediatric population and, 664
therapeutic window, 223
Steenland, K.
organophosphate insecticide exposure research, 319
Stein, A.A.
1-chloroacetophenone research, 462
Stenhouse, John
synthesis of chloropicrin, 117
Steroids. *See also* Corticosteroids
palytoxin intoxication treatment, 621
Stimson, Secretary of State Henry L.
letter from Gen. MacArthur, 44–45
Stimulants
description and effects of, 418
STM. *See* Sacco triage method
Stokes mortars
description, 118, 119
Stoughton, R.W.
2-chlorobenzylidene malononitrile research, 444
Strasbourg Agreement of 1675
description, 136
Strategic National Stockpile
description and role, 765
pediatric-ready medications and, 678
"push packages" of pharmaceutical and supplies, 765
Strategy for Homeland Defense and Civil Support
objectives, 758
Stroke

seizure-related brain damage and, 226
Stubbs, Maj. Gen. Marshall
Soviet chemical weapons threat comments, 56
STX. *See* Saxitoxin
Substance abuse and dependency
screening of chemical agent workers, 602–603
US Army policies, 602–603
Succinylcholine
butyrylcholinesterase and, 164
pediatric population and, 666
Sudecon Decontamination Wipes
incapacitating agents and, 470
Sulfur dioxide
common sources of, 345
Sulfur mustard. *See* Mustard agent
Super Bowl of 2001
CDC Enhanced Surveillance Program data, 622
Suschitzkey, H.
dibenz*[b,f]*-1,4-oxazepine research, 467, 468
Swanston, D.W.
dibenz*[b,f]*-1,4-oxazepine research, 468
1-chloroacetophenone research, 460
Switzerland
Russia's elimination of chemical weapons and, 145
"Symptomology, Pathology and General Treatment of Gas Cases" (Gilchrist), 91
Syria
Yom Kippur War and, 61
Systox
blood cholinesterase inhibition and, 165

T

T-2 mycotoxin
CDC categorization as a category B threat agent, 616
T-shells. *See* Xylyl bromide
Tabershaw, I.R.
organophosphate insecticide exposure research, 320
Tabun
advantages of as a chemical weapon, 47
assays for, 699
behavioral effects of exposure, 175
capture of German facility for manufacturing, 50–51, 157
chemical structure (figure), 694
development of, 693
German production of, 48, 119, 156, 693
Iran-Iraq War and, 157, 195–196
molecular model (figure), 166
muscle necrosis and, 318
properties of, 3
pulmonary system effects, 174
pyridostigmine bromide pretreatment, 199, 201
Soviet Union production of, 156
synthesis of, 156
testing of, 47
toxicity and lethality of, 47, 693
toxicological studies, 322
volatility of, 168
Taniyama, S.
palytoxin research, 620
TDG. *See* Thiodiglycol
TDG-sulfoxide. *See* Thiodiglycol sulfoxide
Tear gas. *See* Incapacitating agents
Teflon. *See* Polytetrafluoroethylene
TEN. *See* Toxic epidermal necrosis
Terbutaline
chlorine inhalation treatment, 353
Termination examinations for chemical workers
changes in duties and, 601–602
timing of, 601
Terrorist attacks
advantages of chemical agents for, 126–127
Al Qaeda, 129
"Alphabet Bomber," 127
Aum Shinrikyo, 4, 125, 127–128, 129, 158, 178, 181–182, 193, 196–197, 223, 244, 316, 317, 321, 492, 518, 540, 657, 695–696, 699, 754
chemical terrorism incidents, 126–129
The Covenant, the Sword, and the Arm of the Lord, 127
cyanide plot against the US Embassy, Italy, 128
"domestic terrorism" definition, 126
fear of future chemical attacks, 560
military installation protection, 126
September 11, 2001, attacks, 65, 560
"terrorism" definitions, 125–126
"terrorist" definition, 125
William Krar, 128–129
Test-Mate kit
field-forward assay for organophosphorus exposure, 693, 702, 704
Tetraethyl pyrophosphate
development of, 46–47
synthesis of, 46, 156
Tetrahydroaminacridine
Alzheimer's disease treatment, 426
3-quinuclidinyl benzilate intoxication treatment, 426
Tetrodotoxin
chemical structure (figure), 623
clinical signs and symptoms of poisoning, 624–626
laboratory findings, 626–627
lethal dose, 623–624
mechanism of action, 623
monitoring, 627
physical examination and, 626
protection issues, 628
signs and symptoms of intoxication, 628
sodium channel effects, 617, 623
sources of, 622
stability, 627, 628
surveillance, 628
synthesis, 622–623
toxicity, 623–624
treatment, 627, 628
Thiodiglycol
analysis methods for urine samples to measure thiodiglycol or thiodiglycol and thiodiglycol-sulfide (table), 710
mustard agent exposure and, 707, 708–711, 713–718
target analytes for analysis methods outlined in Table 22-7 (table), 711
Thiodiglycol sulfide
analysis methods for urine samples to measure thiodiglycol or thiodiglycol and thiodiglycol-sulfide (table), 710
target analytes for analysis methods outlined in Table 22-7 (table), 711
Thiodiglycol sulfoxide
mustard agent exposure and, 708, 710–711, 716–718
Thiosulfate. *See* Sodium thiosulfate
Thirty Years War
use of toxic smoke projectiles, 11
Thomas, S.J.
mustard agent exposure treatment, 279
3,4-methylene-dioxymethylamphetamine
description and effects of, 418
3-quinuclidinyl benzilate
analytical methods for exposure to, 739

Chemical Corps research, 414, 422–424
chemical structure (figure), 739
clinical pharmacology, 422–423
delirium features, 423–424
description and incapacitating effects, 422, 427, 738
development of, 3, 59
duration of action, 738
inhalation studies, 422–423, 427
lethal dose, 738
mechanism of action, 738–739
molecular weight, 738
parameter definitions, 423
physostigmine treatment for intoxication by, 426, 523
placidity and, 425
routes of administration, 422
safety of, 427
stockpiles of, 739
summary of BZ and fentanyl derivatives (table), 429
tetrahydroaminacridine treatment for intoxication by, 426
therapeutic ratio, 427
use of by Iraq during the Persian Gulf War, 413
weaponization of, 738
Thucydides
History of the Peloponnesian War, 10, 78
TICs. *See* Toxic industrial chemicals
TIM. *See* Toxic industrial material
Tissue sample analysis
mustard agent, 726
Tobacco use. *See* Smoking
Tobramycin
mustard agent treatment, 672
Tooele Army Depot, UT
demilitarization of chemical agents, 141–142, 143, 157
Topical antibiotics. *See also* Antibiotics
treatment of mustard agent exposure, 280, 672
Torngren, S.
individual protective equipment research, 543–544
Torsade de pointes
nerve agent exposure and, 179
Total-body cooling
neuroprotectant use, 232
Toxic Chemical Agent Safety Standards
protection levels for workers, 596
Toxic epidermal necrosis
compared with skin injuries from mustard agent, 278, 279
Toxic industrial chemicals. *See also* Toxic industrial material; *specific agents*
common sources, 340
definitions of airborne toxic material (table), 340
description, 340
forms of, 340
history and use, 341–345
inhalational injury from, 340–365
mechanism of injury, 340, 355, 356–357
mechanisms of toxicity, 345–353
military uses, 341
nonmilitary uses, 341–345
potential for accidental or deliberate exposure, 341
respiratory protection equipment, 563
triage considerations, 519–520, 522, 523
US Army Center for Health Promotion and Prevention Medicine toxic industrial chemicals (table), 343–344
Toxic industrial material. *See also* Toxic industrial chemicals
detection and identification, 580–581
individual protection, 580
respiratory protection equipment, 563
use in improvised explosive devices, 580
Toxic smokes
common sources, 345
early military use, 10–11, 78, 341
pathophysiological effects, 350
uses for, 134
Toxicological studies
nerve agents, 322
Toxins. *See also specific agents*
accidental exposure, 616
biotoxin threat, 616
categories of, 614
chemical warfare agent comparison, 616–617
Chemical Weapons Convention definition, 614
delivery methods and use of, 614, 616
emergent threats, 617
established threats, 616–617
food and water supplies and, 616
list of known toxins and their sources (table), 615–616
nature of the threat from, 614
storage capability and use of, 614
terrorism and use of, 614, 633
Transformational medical technologies initiative
description, 647
Treatment of Chemical Agent Casualties, 184
Treatment of incapacitating agent exposure. *See also* Field management of chemical casualties; *specific agents and drugs*
cardiovascular system, 472
eyes, 471
laboratory findings, 472
respiratory tract, 471–472
skin, 471
Treatment of mustard agent exposure. *See also* Field management of chemical casualties; *specific agents and drugs*
airway injuries, 287–290
antimicrobials, 280–281
antioxidants, 282
biologic dressings, 280
bone marrow issues, 288–290, 672
burn centers and, 278
categories of casualties, 277
changing of dressings, 280
debridement, 280, 282, 283–285, 290, 670
decontamination, 277, 312, 670
deep injury treatment, 281, 283
depth of injury assessment, 282–283
dressings, 280, 282, 285
eye injuries, 287
fluid and electrolyte monitoring, 278, 279
gastrointestinal tract issues, 288, 290
goal of blister management, 670
growth factors, 285–286
hospitalization issues, 262, 277, 281
indocyanine green fluorescence imaging, 283
Laser Doppler perfusion imaging, 283
long-term effects, 291
nonsteroidal antiinflammatory drugs, 282
off-gassing and, 282, 671
pain control, 278, 279
pediatric population and, 670–672
return to duty guidelines, 290–291
secondary infection risk, 281, 288–289
skin injuries, 278–287, 670–672
skin substitutes, 286–287
supportive care, 278
topical antibiotics, 280
unroofing and cleansing of blisters, 279–280
vacuum-assisted closure therapy, 287

Treatment of nerve agent exposure. *See also* Field management of chemical casualties; Neuroprotection as a treatment for nerve agent survivors; *specific nerve agents and drugs*
anticonvulsive therapy, 189–190
antidote treatment nerve agent autoinjector, 182–186, 192, 193, 194
atropine therapy, 182–186, 244
cardiac arrhythmia treatment, 190
challenges of administration, 244, 253
decontamination of the patient, 180–181
effect of therapy on median lethal dose in monkeys exposed to soman (table), 199
general principles, 180–190, 244, 316
mild exposure, 192
minimal exposure, 191–192
moderate exposure, 192
moderately severe exposure, 192–193
oxime therapy, 186–189, 197–198
pediatric population and, 663–665
pretreatment considerations, 197–204, 244
protection of the rescuer, 180, 193
psychogenic casualties and, 196
recommended therapy for casualties of nerve agents (table), 191
regimen of antidotal therapy, 223, 244
severe exposure, 193–194
suspected exposure, 191
terminating the exposure, 180–181
timing of administration, 244, 252
treatment by exposure category, 190–194
value of aggressive treatment, 197
ventilatory support, 181–182, 186
"Treatment of Status Epilepticus in Adults: Columbia University Protocol," 231
Treatment of toxic industrial chemical exposure. *See also* Field management of chemical casualties; *specific agents and drugs*
acute medical management, 362–365
airway secretion management, 363–364
clinical care, 365
establishing an airway, 362–363
history assessment for casualties exposed to lung-damaging agents (exhibit), 362
hypotension treatment and prevention, 364–365
hypoxia prevention and treatment, 364
patient history, 361
patient transport, 365
physical assessment for casualties of lung-damaging chemical agents (exhibit), 363
physical examination, 361–362
pulmonary edema treatment, 364
rest from physical exertion, 363
termination of exposure, 362
triage for casualties of lung-damaging toxic industrial chemicals (exhibit), 364
Treaty of Versailles
description, 136
Trench mortars
attacks on the AEF (exhibit), 26
CWS standardization of, 119–120
description, 26
Stokes mortars, 118, 119
Triage of chemical casualties
alternative areas for, 678
benefit of assistance issues, 512–513
challenges unique to, 516
combined injuries and, 522–523
conventional wounds contaminated with chemical agents, 522–523
cyanide and, 518–519, 521, 522, 523
cyanide poisoning, 386
decontamination, 513–514
delayed treatment category, 516, 521, 577
development of a pharmaceutical cache of medications, 678
division triage stations, 94
dynamic nature of, 513, 524
emergent category, 516
essential information for, 512
evacuation issues, 516–517
expectant treatment category, 516, 522, 577
immediate treatment category, 516, 520–521, 577
incapacitating agents and, 520, 521, 522, 523
levels of care, 513
lung-damaging agents and, 519–520, 522, 523
medical management issues, 517–520
minimal treatment category, 516, 521–522, 577
national site setup and control zones for a hazardous materials site (figure), 515
natural course of disease and, 512–513
nerve agents and, 518, 520–521, 522–523
nonemergent category, 516
pediatric population and, 677
placement of teams, 514–516, 547
principles and processes, 512–516, 524
Sacco triage method, 517
START system, 517
treatment, decontamination, and transport linkage, 514–516
triage and treatment area (cold zone), 506
triage area (warm side), 504–505
triage by category and agent, 520–522
"triage" definition, 512
triage for casualties of lung-damaging toxic industrial chemicals (exhibit), 364
US military triage categories, 516–517
vesicants and, 519, 521–522, 523
Triazolam
incapacitating effects, 420
Trichloromethyl chloroformate. *See* Chloropicrin
Trilon group of nerve agents. *See* Sarin; Soman; Tabun
Tropical ataxic neuropathy
cyanide exposure and, 323
Truman, Pres. Harry S
United States ratification of the Geneva Protocol and, 60, 137
Tsuchihashi, H.
VX nerve agent research, 695
TTX. *See* Tetrodotoxin
Turpin, Eugene
secret weapon developed by, 80
22nd Chemical Battalion
mission of, 597
21st century
Operation Enduring Freedom, 65
Operation Iraqi Freedom, 65–66
Russia's use of fentanyl in the Chechen hostage situation, 3, 65, 413
20th Support Command
domestic preparedness role, 763
2-aminothiazoline-4-carboxylic acid
cyanide poisoning and, 376
2-chlorobenzylidene malonitrile
nonmilitary uses, 342
overall effects of, 342
Yemen Civil War and, 341
2-oxothiazolidine-4-carboxylic acid
chemical structure (figure), 736

phosgene and, 736
2-PAM Cl. *See* 2-pyridine aldoxime methyl chloride
2-pralidoxime chloride. *See* 2-pyridine aldoxime methyl chloride
2-pyridine aldoxime methyl chloride
administration considerations, 187, 188–189, 652, 682–683
combined with atropine, 183, 223, 651
dosage considerations, 187, 189, 194
intermediate syndrome treatment, 318
limitations of, 653
nerve agent exposure treatment, 174, 183, 197–198, 244, 316, 651
pediatric population and, 663, 664, 682–683
side effects, 187, 188
soman-induced seizure-related brain damage treatment, 227
treatment of children and, 195

U

Uniformed Services University of the Health Sciences
CBRNE training programs, 768
United Kingdom. *See* Great Britain
United Nations
Bush's and Blair's warning on Iraq's weapons of mass destruction program, 66
Disarmament Committee, 137
Iran-Iraq War and, 63
report condemning the production and stockpiling of chemical weapons, 60
Yemen Civil War and, 58
United States. *See also specific conflicts, leaders, cities, states, military installations, agencies, and departments*
chemical demilitarization program, 141–143, 609–611, 766
Chemical Weapons Convention and, 65, 157
chlorine production, 672
chloropicrin production, 455
diphenylaminearsine production, 464
gas chamber executions with cyanide, 374
Geneva Protocol ratification, 60, 137, 443
Memorandum of Understanding with the Soviet Union on prohibiting chemical weapons, 63
nerve agent weaponization, 3
phosgene production, 345, 672
plans for gas warfare during World War II, 52–53
post-World War I chemical warfare policy, 44–45
Russia's elimination of chemical weapons and, 144
sarin production, 157
stockpile agent destruction (table), 143
US-Soviet weapons destruction agreement, 138
VX nerve agent development and production, 157
World War I experience of chemical warfare, 21–42, 117
University of Maryland Medical Center
coordination with local resources, 678
triage for chemical agent casualties, 677
University of Pennsylvania
neuropeptide research, 420
Upshall, D.G.
dibenz*[b,f]*-1,4-oxazepine research, 467, 469
Urine sample analysis
analysis methods for urine samples to measure thiodiglycol or thiodiglycol and thiodiglycol-sulfide (table), 710
analytical methods, 708–713
application to human exposure, 713, 715–718
collection issues, 692
cyanide poisoning, 734
guidelines for collection, 739
lewisite exposure, 728, 729
mustard agent exposure, 708–718
noninvasive, 692
published reports (1995-2006) of laboratory analysis of human urine samples for glutathione reaction products following a suspected exposure to sulfur mustard (table), 720
published reports (1995-2006) of laboratory analysis of human urine samples for hydrolysis metabolites following suspected exposure to sulfur mustard (table), 719
sample considerations, 739
sample preparation methods for the gas chromatographic/mass spectrometric/mass spectrometric analysis of the sulfur mustard urinary β-lyase metabolites (exhibit), 713
US Air Force
collectively protected expeditionary medical support and, 585
field management of chemical casualties, 490–491
US Army. *See also* Chemical Corps; Chemical Warfare Service; US Department of Defense; *specific divisions and installations*
area medical laboratories, 763–764
binary weapon research, 122–123
Chemical Materials Agency, 142, 143
Chemical Stockpile Emergency Preparedness Program, 142–143
chemical training improvements during the 1980s, 63
Defense Medical Readiness Training Institute, 768
demilitarization of chemical agents, 141–143
destruction of chemical weapons stockpile and, 610–611
Employment of Chemical Agents, 136
field management of chemical casualties, 481, 487, 489
520th Theater Army Medical Laboratory, 693
M20 simplified collective protection equipment and, 587
Medical Department, 79
Medical Management of Chemical Agent Casualties Handbook, 184
reorganization of, 56–57
substance abuse and dependency policies, 602–603
Toxic and Hazardous Materials Agency, 141
Treatment of Chemical Agent Casualties, 184
20th Support Command, 763
US Army Center for Environmental Health Research
biomonitoring device, 631
US Army Center for Health Promotion and Prevention Medicine
domestic preparedness role, 763, 764
US Army Chemical Corps. *See* Chemical Corps
US Army Chemical Materials Agency
chemical accidents or incidents and, 607
missions of, 596–597
US Army Chemical School
CBRNE courses, 769
US Army Materiel Command
chemical accidents or incidents and, 607
US Army Medical Command
domestic preparedness role, 761, 763, 764
resources of, 764
US Army Medical Department
ambulance company dressing stations, 93–94
army-level gas hospitals, 97
base and gas hospitals, 95
bathing of chemical casualties, 92, 93, 95
battalion aid stations, 92–93
bulletins aimed at keeping personnel current on chemical warfare developments, 91
casualty cards, 97
classification of chemical casualties, 94–95
classification of wounded soldiers, 97
company aid posts, 92
defensive gas training, 89
difficulty of carrying "anti-gas" medical equipment, 96
division field hospitals, 95–96
division gas medical officers, 92
division triage stations, 94

evacuation hospitals, 94–95
evacuation in trench *versus* open warfare, 99–101
evacuation methods, 97–99
gas-proofing of dugouts, 93
Headquarters, First Army Corps, memorandum on the evacuation of sick and wounded, 1918 (exhibit), 98
increase in the number of gas casualties and, 91
organization of, 89–101
origination of, 89
Royal Army Medical Corps as basis for, 89
Sanitary Corps staffing, 90
secret field order no. 41, annex no. 7, issued by the Fifth Division, September 9, 1918 (exhibit), 100
separation of chemical casualties from other wounded soldiers, 97
special wards for chemical casualties, 94
specialized hospital gas teams, 92
techniques to detect malingerers, 92
training and education in CBRNE and, 767, 768
uniform procedure for handling chemical casualties, 91
US Army Medical Institute of Infectious Disease
CBRNE training program, 768
Contaminated Casualty Decontamination Course, 763
Hospital Management of CBRNE Incidents Course, 769
Medical Management of Chemical and Biological Casualties Course, 763, 768
US Army Medical Research and Materiel Command
drug acquisition responsibilities, 650
US Army Medical Research Institute of Chemical Defense
"Assay Techniques for Detection of Exposure to Sulfur Mustard, Cholinesterase Inhibitors, Sarin, Soman, GF, and Cyanide," 693
barrier skin creams, 530–532
CBRNE training, 768
chemical casualty site teams, 607
chemical warfare exposure assay development, 693
Contaminated Casualty Decontamination Course, 763
Field Management of Chemical and Biological Casualties Course, 768–769
glove issues in decontamination, 539
Hospital Management of CBRNE Incidents Course, 769
Medical Management of Chemical and Biological Casualties Course, 594–595, 608, 763, 768
role and responsibilities, 5
sample collection, shipping, and storage guidelines, 739–741
Toxic Chemical Training Course for Medical Personnel, 594–595, 608
working conditions, 597
US Army Northern Command
domestic preparedness role, 761, 763, 764
US Army Ordinance Corps
training and education in CBRNE and, 767
US Army Research and Development laboratory
3-quinuclidinyl benzilate monitoring, 739
US Army Soldier and Biological Chemical Command
glove issues in decontamination, 539
US Bureau of Mines
toxic gas research, 89
US Civil War
chemical warfare proposals, 11–12
US Coast Guard
field management of chemical casualties, 491, 492
US Code
"terrorism" definition, 126
US Congress. *See also specific legislation*
antiterrorism training bill, 125
binary chemical weapon development restrictions, 124
demilitarization of chemical agents and, 142
law controlling storage, testing, and disposal of agents outside the United States, 60
review of binary weapons, 124–125
subcommittee on noxious gases, 21–22
US Defense Intelligence Agency
"Biotechnology: Impact on Biological Warfare and Biodefense," 420–421
US Department of Agriculture
domestic preparedness role, 761
Laboratory Response Network and, 765–766
US Department of Defense. *See also* US War Department
analysis of possible accidental battlefield exposure to chemical agents during Operation Desert Storm, 129–130
Army reorganization, 56–57
Assembled Chemical Weapons Alternatives Program, 142
chemical agent medical countermeasure requirements, 646
Chemical Stockpile Emergency Preparedness Program role, 766–767
defense acquisition executive responsibilities, 646
domestic preparedness roles, 755, 758–764, 767–770
5000 series documents, 647–648
incapacitating agents characteristics, 412
investigational new drugs and, 650
military installation protection from terrorist attacks, 126
National Medical Chemical and Biological Advisory Team, 764
Project BioShield and, 251
pyridostigmine bromide informed consent issues, 204, 650–651
Quadrennial Defense Review Report of 2006, 758, 770
requests for assistance in chemical casualty management, 494
support for civilian chemical casualty management, 493
support to civil authorities, 761–764
"terrorism" definition, 125
22nd Chemical Battalion support operations, 597
2-chlorobenzylidene malononitrile variation creation, 444
US Department of Energy
domestic preparedness role, 755
US Department of Health and Human Services
Chemical Stockpile Emergency Preparedness Program role, 766
disaster and medical response to mass casualty events, 492
drug acquisition responsibilities, 650
first responder policy recommendations, 493
homeland security role, 755
Laboratory Response Network and, 765–766
National Response Framework coordination guidelines for, 761
Project BioShield and, 251
Strategic National Stockpile and, 765
US Department of Homeland Security
color-coded threat condition chart, 755
creation of, 755
homeland security councils and, 755
Laboratory Response Network and, 765–766
lead federal agency for domestic incident management, 755
National Incident Management System, 492, 755–756
National Response Framework, 758
National Response Plan, 755–756
Office for Domestic Preparedness, 770
organizational outline for incident management command (figure), 757
Project BioShield and, 251
state and regional coordination and, 759
Strategic National Stockpile and, 765
US Department of State
"terrorism" definition, 125
US Environmental Protection Agency

Chemical Stockpile Emergency Preparedness Program role, 766
demilitarization of chemical agents and, 142, 143
levels of protection, 580
waste water disposal issues, 546
US Food and Drug Administration
"animal rule" for drug product approval, 647, 651
anticholinesterase treatment for Alzheimer's disease, 158
clinical trial phases, 647
investigational new drug submissions, 649, 650
Laboratory Response Network and, 765–766
medical chemical defense acquisition programs and, 646, 647, 648–653
"off-label" uses for drugs, 650
phosgene inhalation treatment guidelines, 354
Project BioShield and, 251
pyridostigmine bromide approval, 204
Reactive Skin Decontamination Lotion approval, 536
US General Accounting Office
CBRNE training programs and, 768
US Joint Forces Command
domestic preparedness role, 764
US Marine Corps
chemical/biological incident response force, 762–763
field management of chemical casualties, 489–490
Joint Non-lethal Weapons Directorate, 431
M20 simplified collective protection equipment and, 587
US Navy
binary weapon research, 123
field management of chemical casualties, 489, 491–492
hospital ships, 491–492
US Office of Management and Budget
Project BioShield funding, 251
US Postal Service
oleoresin capsicum use, 443
US War Department. *See also* US Department of Defense
chemical warfare plan, 22
chemical weapon stockpiles and, 44
gas warfare function centralization, 22
Memorandum on Gas Poisoning in Warfare with Notes on its Pathology and Treatment, 90
Notes on Gas as a Weapon in Modern War, 90
USACHPPM. *See* US Army Center for Health Promotion and Prevention Medicine
USAMRICD. *See* US Army Medical Research Institute of Chemical Defense
USAMRIID. *See* US Army Medical Institute of Infectious Disease
USNS *Comfort*
hospital ship capability, 491
USNS Mercy
hospital ship capability, 491
USS *Bon Homme Richard*
hospital ship capability, 491
USS *Kearsage*
hospital ship capability, 491

V

V-series nerve agents. *See also specific agents*
categorization of (exhibit), 47
production during the 1950s, 55
weaponization of, 3
VAC. *See* Vacuum-assisted closure therapy
Vacuum-assisted closure therapy
contraindications to, 287
mustard agent injuries, 287
van Galen, Christoph Bernhard
use of toxic smoke projectiles, 11
Van Hooidonk, C.
decontamination research, 534, 536
Vanderbelt, J.M.
cyanide poisoning research, 396
Vedder, Lt. Col. Edward
career of (exhibit), 103
chemical training for soldiers and, 103
comments on Shryock, 108
Medical Aspects of Chemical Warfare, 104
1-chloroacetophenone research, 462
Vee
physostigmine isolation, 46
Ventilatory support
arrhythmias and, 190
atropine and, 181, 186, 193
hydrogen cyanide inhalation, 354
incapacitating agent exposure and, 471–472
intermediate syndrome, 318
mass casualty incidents, 181, 519–520
mechanical devices for, 181
mouth-to-mouth ventilation, 181, 675
mustard agent injuries, 288–289, 672
nerve agent exposure treatment, 181–182, 520
triage issues, 519–520
Vesicants. *See also* Incapacitating agents; Lewisite; Mustard agent; Phosgene oxime
chemical, physical, environmental, and biological properties of vesicating agents (table), 260–261
conventional wounds contaminated with, 523
description, 260, 667
management of vesicant exposures (table), 671
pediatric population and, 667–673
prolonged morbidity from, 667
triage considerations, 519, 521–522, 523
types of, 260–261
Veterans Administration
phosgene exposure research, 325–326
study on the effects of mustard agent and lewisite exposure, 312–313
Viala, B.
2-chlorobenzylidene malononitrile research, 471
Vietnam War
Agent Orange use, 341
defoliant use, 105
mustard agent use, 57
tear gas use for clearing tunnels, 105
2-chlorobenzylidene malononitrile use, 444
Vinci, Leonardo da
poison projectile proposal, 11
Vision. *See* Eyes
Volunteers
anticholinergic deliriant testing on, 424–425
effects of soman on acetylcholinesterase activity in whole blood from human volunteers who had taken pyridostigmine bromide (figure), 706
effects of soman on acetylcholinesterase activity in whole blood from human volunteers who were given an increasing dose of huperzine A (figure), 707
medical research on human volunteers during the 1950s, 55
1-chloroacetophenone testing on, 461
von Deimling, Gen.
chemical warfare comments, 15–16
von der Linde, Hans-Jürgen
sarin research, 47, 156
von Krueger, Gerde
organophosphorus compound research, 47
von Tappen, Hans

T-shell development, 14
VR nerve agent
description, 156
toxicity of, 168
vapor hazard, 168
volatility of, 168
VS nerve agent
weather conditions and, 135
VX nerve agent
additives for, 135
assays for, 699
barrier creams and, 531
behavioral effects of exposure, 175–176
carboxylesterase and, 246
chemical structure (figure), 694
chloroperoxidase and, 250
clinical effects, 316
eye effects of exposure to, 170
incapacitating effects, 416
inhibition of blood ChE activity, 165
land mine delivery, 120–121
molecular model (figure), 166
mortality from, 316
neuropsychiatric effects, 320
plasma-derived human butyrylcholinesterase and, 245–246, 247, 249
projectile delivery, 121
pulmonary system effects, 174
RBC-ChE inhibition, 165
relation of cholinesterase activity to vomiting after exposure to (table), 166
routes of exposure, 695
skin effects, 529
soap and water decontamination, 533, 534
synthesis and production of, 157
toxicity of, 693, 695
vapor hazard, 168
volatility of, 135, 168, 316
Vycudilik, W.
urine sample analysis for mustard agent, 708, 713

W

Wada, S.
mustard agent exposure research, 314
Waitt, Maj. Gen. Alden H.
assessment of the future of chemical warfare in 1946, 54
chemical training for soldiers and, 103–104
post-World War II discovery of German gas reserves, 104–105
summary of CWS's planning for the next war, 119
Walker, M.C.
ketamine research, 231
Wallace rule of nines, 282
Walter Reed Institute of Research Whole Blood Assay
cholinesterase analysis, 702, 705–706
Ward, Kyle, Jr.
description of nitrogen mustard, 119
Water testing kits. *See* M272 chemical agent water testing kits
Watson, Maj. Gen. Gerald G.
chemical training and, 63
Weather. *See* Wind and weather considerations
Weger, N.
cyanide poisoning research, 394, 395–396
Weigand, D.A.
2-chlorobenzylidene malononitrile research, 451
Weimar, J.T.
2-chlorobenzylidene malononitrile research, 451
Wepfer
cyanide poisoning description, 373
Wet decontaminants
Reactive Skin Decontamination Lotion, 533, 536–537
water issues, 546
White, C.
1-chloroacetophenone research, 462
White, R.G.
1-chloroacetophenone research, 463
White House Office of Homeland Security
creation of, 755
National Strategy for Homeland Security, 755
WILD20
soman-induced seizure-related brain damage treatment, 227
Willder, W.B.
2-chlorobenzylidene malononitrile research, 452
Willems, Jan L.
Iranian mustard casualties, 263, 266, 268, 715
Wils, E.R.J.
skin sample analysis for mustard agent, 726
urine sample analysis for mustard agent, 708–709, 716
Wilson, I.B.
oxime research, 186–187
Wilson, President Woodrow
World War I and, 12, 21
Wind and weather considerations
chemical attacks, 80, 117, 121, 135–136
cold shock, 548–549
decontamination in cold weather, 548–550
hypothermia, 548–549
stages and symptoms of hypothermia (table), 548
Winternitz, M.C.
phosgene exposure research, 325
Wolfe, A.D.
fetal bovine serum AChE research, 245, 246
Wolff, H.C.
anticholinergic deliriant research, 422
Wooten, J.V.
lewisite exposure research, 728
World Health Organization
diphenylaminearsine exposure research, 466
World Trade Center
bombing in 1993, 754
World Trade Organization
CDC Enhanced Surveillance Program data, 622
World War I. *See also* American Expeditionary Forces; *specific battles, battle sites, and countries*
aftermath, 36–37, 41
Allied retaliation against chemical warfare, 18
an attack on a platoon of the 28th Division (exhibit), 27
armistice ending, 36
casualties attributed to gas, 36–37, 41–42, 82, 83, 341
chemical agent production, 117
chemical agents used (in chronological order) (table), 342
chemical attacks involving children and civilians, 656
chemical casualties (table), 79
chemical warfare use by France, Great Britain, and Germany, 12–21, 79–82, 312, 341, 373, 397
chemical weapons, 117–118
chlorine gas use, 2
detailed map of Ypres (figure), 17
Dr. Harvey Cushing's account of Royal Army Medical Corps capabilities, Flanders, Belgium, May 5, 1917 (exhibit), 88
earliest reported description involving chemical warfare on the AEF (exhibit), 22
early Allied chemical warfare plans, 12–13
evacuation in trench *versus* open warfare, 99–101
excerpt from "Take Me Back to Dear Old Blighty!" (exhibit), 89

field sanitation and, 83–85
first airplane gas attacks on American forces (exhibit), 26
first projector attack on the AEF (exhibit), 26
"gas fright" syndrome, 82
gas mask development, 18, 19, 80, 561–562
historical summary of chemical warfare agents used in (table), 38–41
hospitalized casualties, in percentages by causative weapon (figure), 85
incapacitating agent use, 443, 455
initial responses to gas attacks, 82–85
map of Belgian-French border (figure), 16
map of western Europe (figure), 13
medical personnel as victims, 101–102
mustard agent use, 2–3, 15, 18, 20–21, 25–26, 27, 260, 261–262, 530
phosgene use, 2, 734
prewar intelligence and the Second Battle of Ypres, 79–82
profiles of chemists (exhibit), 15
Royal Army Medical Corps role, 85–89
six chlorine-phosgene cloud attacks: British casualties December 1915-August 1916 (table), 83
Spanish influenza and, 101
trichloromethyl chloroformate use, 20
US experience with chemical warfare, 21–42
World War II
capture and detainment of German military scientists in Operation Dustbin, 51
capture of soman research documents, 51
chemical weapon delivery system improvements, 120
demilitarization of captured weapons, 54
German gas reserves, 104–105
Germany's experimental testing of chemical and biological warfare agents in concentration camps, 105, 157
nerve agents and, 3, 48
no-first-use policy on chemical weapons, 51–52
sea dumping of captured chemical weapons, 54
smoke and flames agents and, 104
Zyklon B use in Nazi concentration camps, 15, 51, 105, 373, 397, 656
Worldwide NBC Mask Handbook, 561
Wound decontamination
general considerations, 538
initial decontamination, 538
off-gassing and, 282, 538–539
thickened agents and, 538
wound exploration and debridement, 539
Wurtz, Charles A.
discovery of cyanogen chloride, 116
synthesis of tetraethyl pyrophosphate, 156
tetraethyl pyrophosphate synthesis, 46

X

Xylyl bromide
development and use of, 14, 17, 79

Y

"Yellow cross." *See* Mustard agent
Yemen Civil War
chemical weapons use, 57–58, 262, 341
Compromise of 1970, 58
Yen, D.
cyanide poisoning research, 385
Yeung, D.T.
human paraoxonase 1 research, 251
Yih, J.P.
2-chlorobenzylidene malononitrile research, 451–452, 471
Yom Kippur War. *See* Arab-Israeli Yom Kippur War
Yperite. *See* Mustard agent
Ypres, First Battle of
stalemate result of, 14
Ypres, Second Battle of
casualties, 82
chlorine gas attacks, 14–18, 21, 79–82
detailed map of Ypres (figure), 17
prewar intelligence and, 79–82

Z

Zante, R.
phosgene research, 735
Zeiler, A.G.
phosgene research, 345
Zhukov, Soviet Defense Minister
chemical weapons threat, 56
Zinc oxide
physiological effects, 358–359
toxic effects of exposure, 327
Zyklon B
development of, 15
use in Nazi concentration camps, 15, 51, 373, 397, 656